



Capital  
Markets

# Top 30 Global Ideas for 2022

## Third-Quarter Update

EQUITY RESEARCH | July 5, 2022

For Required Non-U.S. Analyst and Conflicts Disclosures, see page 38.

## Table of Contents

<b>Introduction .....</b>	<b>3</b>	CrowdStrike Holdings, Inc. (NASDAQ: CRWD) .....	20
<b>Top 30 Global Ideas for 2022 — Pricing Data .....</b>	<b>4</b>	DuPont de Nemours, Inc. (NYSE: DD) .....	21
<b>Top 30 Global Ideas for 2022 — Changes This Quarter .....</b>	<b>5</b>	Intact Financial Corporation (TSX: IFC) .....	22
<b>Top 30 Global Ideas — Performance Summary .....</b>	<b>6</b>	Lonza Group AG (SWX: LONN) .....	23
<b>Investment Thesis .....</b>	<b>7</b>	M&T Bank Corporation (NYSE: MTB) .....	24
adidas AG (XETRA: ADS) .....	8	Mastercard Inc. (NYSE: MA) .....	25
The AES Corporation (NYSE: AES) .....	9	The Mosaic Company (NYSE: MOS) .....	26
Alexandria Real Estate Equities, Inc. (NYSE: ARE) .....	10	Palo Alto Networks, Inc. (NYSE: PANW) .....	27
Alimentation Couche-Tard Inc. (TSX: ATD) .....	11	R1 RCM Holdco Inc. (NASDAQ: RCM) .....	28
AltaGas Ltd. (TSX: ALA) .....	12	S&P Global Inc. (NYSE: SPGI) .....	29
American International Group, Inc. (NYSE: AIG) .....	13	Shell PLC (LSE: SHEL; NYSE: SHEL) .....	30
American Tower Corporation (NYSE: AMT) .....	14	Siemens AG (XETRA: SIE) .....	31
Anheuser-Busch InBev SA/NV (BRU: ABI; NYSE: BUD) .....	15	Stericycle, Inc. (NASDAQ: SRCL) .....	32
Brookfield Asset Management Inc. (NYSE: BAM; TSX: BAM.A) .....	16	TELUS Corporation (TSX: T; NYSE: TU) .....	33
Canadian Natural Resources Limited (TSX: CNQ; NYSE: CNQ) .....	17	TransDigm Group Inc. (NYSE: TDG) .....	34
Canadian Pacific Railway Limited (TSX: CP; NYSE: CP) .....	18	UnitedHealth Group Inc. (NYSE: UNH) .....	35
ConocoPhillips (NYSE: COP) .....	19	Veeva Systems Inc. (NYSE: VEEV) .....	36
		WESCO International, Inc. (NYSE: WCC) .....	37

*This report is priced as of market close on July 4, 2022 unless otherwise noted. US-listed companies are priced as of market close on July 1, 2022.*

## Introduction

**Graeme Pearson** – Global Head of Research

**Mark Odendahl** – Head of US Research

**André-Philippe Hardy** – Head of Canadian & APAC Research

**Michael Hall** – Head of European Research & Global Head of Research Product Management

In this note, we present our *Top 30 Global Ideas* for Q3 2022. This list remains one of high-conviction, long-term ideas, with quarterly updates that enable dynamic changes into names that we think offer higher-conviction upside potential.

Since publishing our Q2 update on April 4, 2022, the *Top 30* list has delivered a total return of -17.4% (in USD terms) versus our benchmark, the MSCI World Index, at -15.6%. Year-to-date, the list has delivered a total return of -14.0%, above the benchmark at -20.1%, and since inception of our quarterly list at year-end 2019, the *Top 30* has delivered a total return of +20.8%, above the benchmark at +13.2%.

Recession risk, rising rates and inflation remain key areas of focus across sectors. As of our latest US Equity Strategy [RBC Macroscope](#) update (published June 6, 2022), on a 6-12 month view, our Strategy team continues to believe that stock market leadership is transitioning from Value to Growth and that defensive areas have started to look over-owned and overvalued, while acknowledging near-term risks to that view should equities start to price in a full recession.

With the changes to the *Top 30* list this quarter, we switch into best ideas that we also view as offering more attractive positioning against the current macro backdrop. On an equal-weighted basis, we increase the *Top 30* list's Real Estate and Utilities exposure to overweight versus the MSCI World Index, maintain a modestly overweight position in Financials, and remain

notably overweight Energy and Industrials, driven by the inclusion of individual high-conviction names under coverage.

In **Real Estate**, we add Communications Infrastructure company **American Tower (AMT US)**, which we think is well positioned to benefit from mobile 5G spending by its carrier customers, with accelerating site leasing trends in its core US market as well as many of its international markets. In 2023 and beyond, we believe AMT should post 10%+ AFFO/share growth and an attractive dividend, coupled with inflation protection in most of its international markets given its CPI-linked lease escalators.

In **Utilities**, we add independent power producer **The AES Corporation (AES US)**. We believe AES offers a compelling decarbonization story, potential to become a leader in the clean energy producer space, and attractive valuation relative to defensive utility peers.

In **Health Care**, we add **Lonza Group (LONN SW)**, which we think is positioned to benefit from multi-year structural tailwinds in biologic pharmaceutical manufacturing. We see life science funding concerns as overblown for CDMOs, and our recent supply/demand analysis suggests the long-term growth outlook is de-risked. In our view, the shares appear attractively valued at current levels vs. peers and due to the high return on incremental invested capital (25-30%), as well as opportunities to invest using its strong balance sheet. We remove robotic-assisted surgery company **Intuitive Surgical (ISRG US)** as we see potential for a tightening of hospital capital spending in the near term, elongating sales cycles. That said, we maintain an Outperform rating and continue to view ISRG as uniquely positioned for a multi-year runway of growth.

In **Information Technology** we replace **Twilio (TWLO US)** with **Veeva Systems (VEEV US)**, which we view as offering defensive attributes (Veeva sells mission critical

software to life sciences, a defensive industry), multiple growth drivers, a leading financial model, and reasonable valuation.

In **Consumer Discretionary**, we remove **Amazon.com (AMZN US)** as we see risk to H2/22 outlook in the event of marginal consumer softness and associated excess capacity, while maintaining an Outperform rating. In **Materials**, we remove building solutions manufacturer **Louisiana-Pacific (LPX US)** given potential for near-term headwinds associated with higher interest rates and slowing North American housing growth, while our long-term positive thesis remains intact.

This report contains further detail on our investment thesis for each of the names on the Q3/22 list beginning on page 7. We encourage you to reach out to our team to continue the dialogue regarding their investment ideas.

We see our fundamental work being increasingly augmented by our four flagship research products: [RBC Fusion](#)<sup>™</sup>, [RBC Imagine](#)<sup>™</sup>, [RBC Elements](#)<sup>™</sup>, and [RBC ESG Stratify](#)<sup>™</sup>. RBC Fusion offers peer-reviewed, unique reports on our highest-conviction, most-differentiated calls. RBC Imagine is a series of fundamental research reports focused on disruptive forces that we believe will transform the world. Our RBC Elements work features proprietary insights generated in collaboration with our internal data science team. With RBC ESG Stratify, we separate the signal from the noise on ESG matters with precise, analytical research.

### Top 30 Global Ideas for 2022 – Changes this Quarter

**Additions:** The AES Corporation (AES US), American Tower (AMT US), Lonza Group (LONN SW), Veeva Systems (VEEV US)

**Deletions:** Amazon.com (AMZN US), Intuitive Surgical (ISRG US), Louisiana-Pacific (LPX US), Twilio (TWLO US)



## Top 30 Global Ideas for 2022 — Pricing Data

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price (07/04/2022)	Market Cap (MM)	Price Target	Div. Yield (%)	Implied All-in Return (%)
adidas AG <sup>1</sup>	ADS GR	Piral Dadhania	Outperform	EUR	167.08	32,608	205.00	2.0	24.7
The AES Corporation	AES US	Shelby Tucker	Outperform	USD	21.48	15,272	30.00	3.0	42.6
Alexandria Real Estate Equities, Inc.	ARE US	Michael Carroll	Outperform	USD	148.13	23,908	230.00	3.1	58.4
Alimentation Couche-Tard Inc.	ATD CN	Irene Nattel	Outperform	CAD	51.74	53,442	77.00	0.9	49.8
AltaGas Ltd. <sup>2</sup>	ALA CN	Robert Kwan	Outperform	CAD	26.96	7,560	34.00	3.9	30.0
American International Group, Inc. <sup>3</sup>	AIG US	Mark Dwelle	Restricted	USD	52.02	42,969	Restricted	2.5	Restricted
American Tower Corporation	AMT US	Jonathan Atkin	Outperform	USD	258.40	120,285	282.00	2.2	11.3
Anheuser-Busch InBev SA/NV	ABI BB	James Edwardes Jones	Outperform	EUR	51.54	102,152	65.00	1.5	27.6
Brookfield Asset Management Inc.	BAM US	Geoffrey Kwan	Outperform	USD	45.02	70,515	68.00	1.2	52.3
Canadian Natural Resources Limited	CNQ CN	Greg Pardy	Outperform	CAD	71.85	83,289	85.00	4.2	22.5
Canadian Pacific Railway Limited	CP CN	Walter Spracklin	Outperform	CAD	91.92	85,734	115.00	0.8	25.9
ConocoPhillips	COP US	Scott Hanold	Outperform	USD	90.98	117,678	127.00	4.2	43.8
CrowdStrike Holdings, Inc.	CRWD US	Matthew Hedberg	Outperform	USD	179.25	43,450	232.00	0.0	29.4
DuPont de Nemours, Inc.	DD US	Arun Viswanathan	Outperform	USD	54.75	28,251	84.00	2.2	55.6
Intact Financial Corporation	IFC CN	Geoffrey Kwan	Outperform	CAD	182.67	32,150	216.00	2.2	20.4
Lonza Group AG	LONN SW	Charles Weston	Outperform	CHF	524.80	38,934	650.00	0.6	24.5
M&T Bank Corporation	MTB US	Gerard Cassidy	Outperform	USD	159.71	20,619	190.00	3.0	22.0
Mastercard Incorporated	MA US	Daniel R. Perlin	Outperform	USD	318.24	312,193	417.00	0.6	31.7
The Mosaic Company	MOS US	Andrew Wong	Outperform	USD	46.92	17,365	85.00	1.3	82.4
Palo Alto Networks, Inc.	PANW US	Matthew Hedberg	Outperform	USD	508.25	62,210	680.00	0.0	33.8
R1 RCM Holdco Inc.	RCM US	Sean Dodge	Outperform	USD	21.97	10,095	35.00	0.0	59.3
S&P Global Inc.	SPGI US	Ashish Sabadra	Outperform	USD	343.33	120,614	434.00	0.9	27.3
Shell PLC	SHEL LN	Biraj Borkhataria	Outperform	GBp	2,203.00	166,349	3,000.00	3.8	39.9
Siemens Aktiengesellschaft	SIE GR	Mark Fielding	Outperform	EUR	97.60	79,642	175.00	3.6	82.9
Stericycle, Inc.	SRCL US	Sean Dodge	Outperform	USD	44.37	4,095	82.00	0.0	84.8
TELUS Corporation	T CN	Drew McReynolds	Outperform	CAD	28.58	39,097	36.00	4.6	30.6
TransDigm Group Incorporated	TDG US	Ken Herbert	Outperform	USD	541.69	30,605	750.00	0.0	38.5
UnitedHealth Group Incorporated	UNH US	Ben Hendrix	Outperform	USD	517.40	497,221	588.00	1.0	14.6
Veeva Systems Inc.	VEEV US	Rishi Jaluria	Outperform	USD	204.11	33,051	250.00	0.0	22.5
WESCO International, Inc.	WCC US	Deane Dray	Outperform	USD	105.83	5,323	195.00	0.0	84.3

### Notes:

<sup>1</sup> Subsequent to the July 4, 2022 pricing of the *Top 30 Global Ideas for 2022*, ADS's price target was lowered to EUR 205.00 (from EUR 265.00) on July 5, 2022. See note [here](#).

<sup>2</sup> *AltaGas Ltd. (TSX: ALA) has agreed to sell its Alaskan Utilities to TriSummit Utilities Inc. announced on May 26, 2022. RBC Capital Markets served as financial advisor to AltaGas. The transaction is anticipated to close no later than the first quarter of 2023 and will be subject to customary closing conditions, including State regulatory approvals. This research report and the information herein is not intended to provide voting advice, serve as an endorsement of the transaction or result in procurement, withholding or revocation of a proxy or any other action by a security holder.*

<sup>3</sup> This security is restricted pursuant to RBC Capital Markets policy and, as a result, its continued inclusion in the *Top 30 Global Ideas* list has not been reviewed or confirmed as of the date hereof.

Past performance is not necessarily indicative of future performance. Price performance does not take into account relevant costs, including commissions and interest charges or other applicable expenses that may be associated with transactions in these shares.

Source: Bloomberg and RBC Capital Markets

## Top 30 Global Ideas for 2022 — Changes This Quarter

Company	Pricing Symbol	Analyst	Rating	Trading Currency	Closing Price (07/04/2022)	Market Cap (MM)	Price Target	Div. Yield (%)	Implied All-in Return (%)
<b>Additions this quarter:</b>									
<b>The AES Corporation</b>	AES US	Shelby Tucker	Outperform	USD	21.48	15,272	30.00	3.0	42.6
<b>American Tower Corporation</b>	AMT US	Jonathan Atkin	Outperform	USD	258.40	120,285	282.00	2.2	11.3
<b>Lonza Group AG</b>	LONN SW	Charles Weston	Outperform	CHF	524.80	38,934	650.00	0.6	24.5
<b>Veeva Systems Inc.</b>	VEEV US	Rishi Jaluria	Outperform	USD	204.11	33,051	250.00	0.0	22.5
<b>Deletions this quarter:</b>									
<b>Amazon.com, Inc.</b>	AMZN US	Brad Erickson	Outperform	USD	109.56	1,115,321	144.00	0.0	31.4
<b>Intuitive Surgical, Inc.</b>	ISRG US	Shagun Singh	Outperform	USD	206.10	75,721	340.00	0.0	65.0
<b>Louisiana-Pacific Corporation</b>	LPX US	Paul Quinn	Outperform	USD	54.58	4,454	100.00	1.6	84.8
<b>Twilio Inc.</b>	TWLO US	Rishi Jaluria	Outperform	USD	85.17	15,715	200.00	0.0	134.8

### Note:

Past performance is not necessarily indicative of future performance. Price performance does not take into account relevant costs, including commissions and interest charges or other applicable expenses that may be associated with transactions in these shares.

Source: Bloomberg and RBC Capital Markets

## Top 30 Global Ideas — Performance Summary

Although the *Top 30* is not intended to be a relative product, having been created to capture RBC Capital Markets' best ideas on an absolute basis, we compare the performance of the *Top 30* to the MSCI Developed World Index and regional indices to provide context for its returns. See the performance tables below for Q2 2022 (April 4, 2022 to July 4, 2022) and since inception (December 2019).

Ticker	Company	Total Return Q2/2022 (in local currency)	Total Return Q2/2022 (in USD)
SHEL LN	Shell PLC	4.8%	-3.1%
UNH US	UnitedHealth Group Incorporated	1.3%	1.3%
IFC CN	Intact Financial Corporation	-0.5%	-3.1%
MTB US	M&T Bank Corporation	-2.4%	-2.4%
ALA CN	AltaGas Ltd.	-3.9%	-6.5%
ABI BB	Anheuser-Busch InBev SA/NV	-5.3%	-10.6%
CP CN	Canadian Pacific Railway Limited	-5.8%	-8.3%
ATD CN	Alimentation Couche-Tard Inc.	-6.9%	-9.3%
CNQ CN	Canadian Natural Resources Limited	-8.0%	-10.4%
COP US	ConocoPhillips	-8.5%	-8.5%
LPX US	Louisiana-Pacific Corporation	-11.3%	-11.3%
MA US	Mastercard Incorporated	-12.4%	-12.4%
T CN	TELUS Corporation	-13.3%	-15.5%
SPGI US	S&P Global Inc.	-15.6%	-15.6%
PANW US	Palo Alto Networks, Inc.	-16.8%	-16.8%
RCM US	R1 RCM Holdco Inc.	-17.7%	-17.7%
AIG US	American International Group, Inc. <sup>1</sup>	-17.9%	-17.9%
TDG US	TransDigm Group Incorporated	-18.8%	-18.8%
ADS GR	adidas AG	-19.1%	-23.6%
WCC US	WESCO International, Inc.	-19.8%	-19.8%
BAM US	Brookfield Asset Management Inc.	-21.0%	-21.0%
CRWD US	CrowdStrike Holdings, Inc.	-21.3%	-21.3%
SIE GR	Siemens AG	-23.2%	-27.5%
SRCL US	Stericycle, Inc.	-24.7%	-24.7%
DD US	DuPont de Nemours, Inc.	-26.4%	-26.4%
ARE US	Alexandria Real Estate Equities, Inc.	-27.5%	-27.5%
MOS US	The Mosaic Company	-28.6%	-28.6%
ISRG US	Intuitive Surgical, Inc.	-32.5%	-32.5%
AMZN US	Amazon.com, Inc.	-33.0%	-33.0%
TWLO US	Twilio Inc.	-49.8%	-49.8%
Average total return for RBC CM Top 30 Global Ideas in Q2 2022		-16.2%	-17.4%

		Total Return (in local currency)		
		Q2/2022	2022 (Year-to-date)	Since Inception (Not annualized)
<b>Indices</b>				
SXXP Index	STOXX Europe 600 Index	-9.1%	-14.4%	6.7%
AS51 Index	S&P/ASX 200 Index	-11.1%	-8.7%	10.8%
SPTSX Index	S&P/TSX Composite Index	-12.6%	-9.0%	20.3%
SPX Index	S&P 500 Index	-15.5%	-19.6%	23.2%
NDDUWI Index	MSCI World Net Total Return US	-15.6%	-20.1%	13.2%
RBC CM Top 30 Global Ideas		-16.2%	-12.5%	22.2%

		Total Return (in USD)		
		Q2/2022	2022 (Year-to-date)	Since Inception (Not annualized)
<b>Indices</b>				
SXXP Index	STOXX Europe 600 Index	-14.2%	-20.9%	-1.0%
SPTSX Index	S&P/TSX Composite Index	-14.9%	-10.6%	21.3%
SPX Index	S&P 500 Index	-15.5%	-19.6%	23.2%
NDDUWI Index	MSCI World Net Total Return US	-15.6%	-20.1%	13.2%
RBC CM Top 30 Global Ideas		-17.4%	-14.0%	20.8%
AS51 Index	S&P/ASX 200 Index	-18.5%	-13.8%	8.3%

**Notes:** Q2 2022 performance calculated from the time of publishing the *Top 30* Q2 2022 update before market open on April 4, 2022 to market close on July 4, 2022. Past performance is not necessarily indicative of future performance. Price performance does not take into account relevant costs, including commissions and interest charges or other applicable expenses that may be associated with transactions in these shares.

<sup>1</sup>This security is restricted pursuant to RBC Capital Markets policy and, as a result, its continued inclusion in the *Top 30* Global Ideas list has not been reviewed or confirmed as of the date hereof.

Source: Bloomberg and RBC Capital Markets



---

## Investment Thesis

---

## adidas AG (XETRA: ADS)

RBC Europe Limited

Piral Dadhania (Analyst) +44 0 20 7429 8644, [piral.dadhania@rbccm.com](mailto:piral.dadhania@rbccm.com)

**Rating: Outperform**

**Closing Price: EUR 167.08**

**Price Target: EUR 205.00\***

**Implied All-in Return (%): 24.7**

\* Subsequent to the July 4, 2022 pricing of the *Top 30 Global Ideas for 2022*, ADS's price target was lowered to EUR 205.00 (from EUR 265.00) on July 5, 2022. See note [here](#).

### Investment summary

**We have an Outperform rating on adidas and €205 price target.**

adidas product momentum has not been strong enough relative to competitors in recent years (even if brand momentum has remained strong). We expect this to improve given management's confidence around its product pipeline for 2022, coupled with the upcoming Sportswear launch and expectations of a more normalized environment post 1H22.

Depressed comparatives, low sentiment on China (and gradual recovery), pricing from mid-2022, and Qatar World Cup (late 2022) should all contribute to an accelerating revenue growth profile which would be supportive for the equity story in our view.

Valuation is supportive for ADS vs its sporting goods peers.

### Valuation

We use a DCF analysis to derive a 12-month price target of €205. The implied return to our price target supports our Outperform rating. At our price target, ADS would trade at 18x FY23E P/E which is below its historical average of 23x offering potential valuation upside.


The core assumptions behind our DCF valuation are a WACC of 9.0% (incorporating a beta of 1.1, risk-free rate of 3.0%, equity risk premium of 5.5%, and pre-tax cost of debt of 3.0%), medium-term cash flow growth of +5% per year (years 5–10), and 2.5% terminal growth rate.

Our 2.5% terminal growth rate reflects both the sporting goods industry (healthy living, low-cost global brand participation, emerging market exposure) and adidas' #2 market-leading position.

### Risks to rating and price target


The main company-specific risks include: 1) US business does not reach scale to contribute meaningfully to group earnings; 2) competitors increase A&P spend; 3) product cycle is not successful; 4) consumer trends favour smaller and less well-known brands; and 5) structural dilution of high China segmental margins.

### Exhibit 1 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 2 - Forward consensus P/E history



Source: Factset

**Most recent industry note: [link](#)**



## The AES Corporation (NYSE: AES)

RBC Capital Markets, LLC

Shelby Tucker, CFA (Analyst) (212) 428-6462, [shelby.tucker@rbccm.com](mailto:shelby.tucker@rbccm.com)
**Rating: Outperform**
**Closing Price: USD 21.48**
**Price Target: USD 30.00**
**Implied All-in Return (%): 42.6**

### Investment summary

AES is a global, leading clean energy player contracting 3-4GW/year with potential to upsize to 4-5GW/year by the middle of the decade. We believe this pipeline will support largely contracted renewables growth and drive 7.4% EPS CAGR through 2025. LNG development in the Caribbean and Vietnam enhances stability of cash flows. We believe a known coal retirements carves a visible path towards a clean energy profile and could lead to valuation multiple expansion in the future. Early investments in emerging business ventures complements AES's core business and could provide long-term upside as in the case of Fluence.

**Potential catalysts include:** 1) extension of federal tax incentives and/or new ITC for energy storage; 2) acceleration in grid-scale and distribution energy resource deployment; 3) commodity prices improve across various SBUs; 4) hydrology improves in South America; and 5) annual run-rate backlog increases.


### Valuation

We derive our price target of \$30 from a sum-of-the-parts analysis by applying different EV/EBITDA multiples to 2023E EBITDA. 1) **US and South America:** 9x multiple to reflect higher levels of contracted earnings and strong renewables backlog; 2) **MCAC and Eurasia:** 7x multiple reflects contracted LNG development with limited commodity risk despite lower growth potential than the Americas; and 3) **Corporate:** 4x multiple. This results in a blended EV/EBITDA multiple of 8.6x and equity value of \$16.7B or \$24/share at AES's core business. We estimate AES's 30% ownership in FLNC and Uplight to be worth \$2.3/share and \$0.6/share. Finally, we add \$3.7/share to AES's renewable development platform based on an economic value add analysis using 10% equity return. Our price target supports our Outperform rating.

### Risks to rating and price target


Risks to rating and price target include: 1) new generation projects fail to earn expected ROEs; 2) increased geopolitical risk; 3) recontracting price comes in lower; 4) hydrology issues lead to earnings volatility; and 5) Gas/LNG assets fall out of favor.

### Exhibit 3 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 4 - Forward consensus EV/EBITDA history



Source: Factset

**Most recent company note: [link](#)**

## Alexandria Real Estate Equities, Inc. (NYSE: ARE)

RBC Capital Markets, LLC

Michael Carroll, CFA (Analyst) (440) 715-2649, [michael.carroll@rbccm.com](mailto:michael.carroll@rbccm.com)

Rating: Outperform

Closing Price: USD 148.13

Price Target: USD 230.00

Implied All-in Return (%): 58.4

### Investment summary

Alexandria Real Estate Equities, Inc. is the largest public life sciences REIT and one of the larger public REITs. We believe ARE will drive healthy organic and external growth with positive leasing trends in its in-service and development portfolios.

### Potential catalysts

**Drug approval trends appear healthy.** FDA drug approvals hit a lull in '16, but 48 novel drugs were approved in '19, 53 in '20, 50 in '21, and 14 YTD. Tenants are more likely to make real estate decisions once they have an approved drug.

**COVID-19 could increase demand for space.** COVID-19 has increased awareness around the need for life science products and R&D. This could lead to incremental demand for tenant's products and research and, in turn, raise demand for life science space.

**Developments/redevelopments should drive growth.** ARE has made solid progress advancing the development pipeline and management has also identified more than ~36.6 million SF of near-term, intermediate-term, and future development projects that should add significant value.

### Valuation

Our \$230/sh price target represents a slight premium to our 1Q23 NAV estimate of \$227.85/sh. We believe this is warranted by the strength of the life science sector and the company's proven operating platform, solid tenant base, and strong balance sheet. Our target reflects ~27.0x our 2024 AFFO estimate (below the trailing 8-quarter average of 29.5x) and a ~\$1,000/SF

valuation. Our price target supports our Outperform rating.

**Net asset value:** Our in-place NAV estimate is \$192.84/sh assuming a 4.35% cap rate. We expect ARE to create value over time and therefore our NAV estimate of \$219.29/sh at YE22 (2023 est.) increases to \$247.87/sh at YE23 (2024 est.).

### Risks to rating and price target

The greatest risks to our estimates, recommendation, and price target relate to general economic trends including, but not limited to, job growth, health-care expenditures, new biotechnology office supply, and access to capital. ARE's tenants require significant funding for the research, development, and clinical testing of products. Tenant products are also subject to regulatory approvals. Higher raw material and labor costs related to development or redevelopment activities could also negatively impact investments. Additional risks, including the threat of terrorism, weather, and key personnel changes, are outlined in the company's filings with the Securities and Exchange Commission.

### Other company-specific risks


**Biotechnology sector could be binary.** The tenant sector can have binary events. For example, ARIA expanded its space with ARE and later announced safety concerns around its blockbuster drug, sending the shares down as much as 80%.

**Supply chain disruptions could slow development.** The pandemic has led to widespread supply chain disruption and management noted that some items used in their

developments are delayed. However, the team has been proactive mitigating any supply chain related issues.


**COVID could impair traditional office demand.** The long-term impact of COVID on demand for office space remains to be seen. ARE generates ~18% of annual rents from tenants using more traditional office space.

### Exhibit 5 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 6 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)

## Alimentation Couche-Tard Inc. (TSX: ATD)

RBC Dominion Securities Inc.

Irene Nattel (Analyst) (514) 878-7262, [irene.nattel@rbccm.com](mailto:irene.nattel@rbccm.com)
**Rating: Outperform**
**Price Target: CAD 77.00**
**Closing Price: CAD 51.74**
**Implied All-in Return (%): 49.8**

### Investment summary

**Despite challenging macro backdrop, multiple avenues for growth**, underpinned by: i) top-line momentum from a more focused, data-driven approach to merchandising/promotional strategies; ii) well-defined initiatives and strategies to optimize procurement; iii) focus on localized merchandise pricing, promotions, and assortments; iv) innovative fuel initiatives, including rollout of Circle-K gas; v) cost optimization; vi) network development; and vii) opportunistic acquisitions.

**On track to deliver F23 EBITDA objective of \$5.1B excluding M&A.** Solid underlying operating performance aided by focused execution of strategies outlined at mid-2021 investor event to deliver “double again” objective.

**Industry performance in North America through COVID and during prior downturns reinforces defensive sector attributes.** Despite high gas prices/opex increases, sustained elevated gas margins should enable ATD to offset gallon weakness related to dislocations.

**Attractive geographic diversification** with >85% of GP\$ generated outside Canada.

**Real-world EV R&D lab in Norway.** ATD is the only North American c-store player with a strong footprint in Norway, the global leader in EV sales. With the operation of charging stations on its sites in addition to home and office chargers, ATD is gaining valuable insight into consumer behaviour/revenue opportunities.

**Strong B/S + FCF profile** with forecast FCF well in excess of \$2B to fund activity on NCIB (F23 program up to 10%

of float), dividend growth, debt repayment, and acquisitions. Adjusted net debt/EBITDAR sustained below 1.5x despite activity on NCIB, well below the post-SFR peak of 3.6x, with normalized estimated balance sheet capacity in excess of US\$15B.

### Valuation


Taking the midpoint of 19x Q4/F24E (Apr C24E) TTM EPS and 11.5x Q4/F24E TTM EBITDA drives our price target of \$77, which supports our Outperform rating. The EBITDA multiple is consistent with the average of the five-year range, reflecting overall sector valuation trends, and supported by ongoing strong normalized underlying performance, relatively recession-resistant business model, and benefits from prior-period M&A. We believe the multiples are also appropriate relative to our c-store coverage universe based on relative investment attributes.

### Risks to rating and price target

Normalization of gas margins without volume improvement would result in earnings below expectations. Substantial dislocation in inside store volumes could reduce inside-store contribution. Although c-stores typically are relatively recession-resistant, ~50% of US c-store customers have incomes ≤\$60k and could be hard-hit by a recession as inflation reaches 40-year highs and interest rates rise. With ATD’s diversified geographic footprint, the risk profile of forecasts includes multiple geographies and currencies and economic and operating environments, each of which is being impacted at differing levels by current dislocation in Europe and surging energy prices.


Potential M&A not included in our forecasts could result in earnings/share price that differs from forecasts.

### Exhibit 7 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 8 - Forward consensus P/E history



Source: Factset

**Most recent company note:** [link](#)

## AltaGas Ltd. (TSX: ALA)

RBC Dominion Securities Inc.

Robert Kwan, CFA (Analyst) (604) 257-7611, [robert.kwan@rbccm.com](mailto:robert.kwan@rbccm.com)
**Rating: Outperform**
**Price Target: CAD 34.00**
**Closing Price: CAD 26.96**
**Implied All-in Return (%): 30.0**

### Investment summary

We expect the shares of AltaGas to outperform its peers for the following reasons:

**Is AltaGas a utility or a midstreamer? The market seems to be saying “neither.”** AltaGas’s guidance is for 55% of 2022E EBITDA to come from the US regulated gas distribution utilities (Maryland, Virginia, Michigan, Alaska, and Washington, D.C.) and the remainder from midstream assets (net of corporate costs). With relative balance, we find that utility investors, particularly those looking to play defence, are not enamoured with the higher-risk midstream business, while we find that WCSB-focused midstream investors have historically looked to pure-play stocks levered to industry trends.

**Additional asset monetizations could continue to drive material upside in the stock.** With the market's positive response to the sale of the Alaskan utilities, we see continued upside if the company looks to monetize additional assets. While MVP was an obvious asset sale candidate given it was a non-operated minority interest that also benefitted from an ability to greatly reduce debt/EBITDA (given AltaGas would only book equity earnings), we still believe that the company has options to monetize an asset, or assets, that could reduce leverage and eliminate various risks for MVP (e.g., whether it happens at all, timing of a sale and/or asset sale valuations changing).

**Potential catalysts:** the sale of the Mountain Valley Pipeline; sale of utility assets; new long-term take-or-pay contracted infrastructure projects with strong counterparties; additional tolling contracts for West Coast LPG exports; and higher-than-expected frac spreads and/or LPG export margins.


### Valuation

Our \$34.00/share price target is based on our sum-of-the-parts analysis that results in values of \$31–\$37/share. Our valuation includes an 18–20x 2023E P/E valuation for the former WGL utilities, which is close to the average for highly regulated names, with a slight adjustment higher for M&A valuations in the space with a 27–29x P/E M&A-type valuation for SEMCO, particularly following the announced sale of the Alaskan utilities at a similar valuation. For Midstream, we use an 11–12x EV/EBITDA multiple, which is consistent with valuations for the Canadian midstream peers with similar assets and business mix. We believe that the risk-adjusted expected total return to our price target supports our Outperform rating on the shares.

### Risks to rating and price target


Risks to our price target and rating include negative regulatory decisions, the inability to complete and/or successfully monetize its stake in the Mountain Valley Pipeline, NGL spreads or gas volumes that meaningfully differ from our forecast, projects/acquisitions that fail to gain the confidence of investors, dilutive actions to maintain the BBB-credit rating, and natural gas prices and drilling trends in the WCSB.

### Exhibit 9 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 10 - Forward consensus P/E history



Source: Factset

**Most recent company note:** [link](#)

## American International Group, Inc. (NYSE: AIG)

RBC Capital Markets, LLC

Mark A. Dwelle, CFA (Analyst) (804) 782-4008, [mark.dwelle@rbccm.com](mailto:mark.dwelle@rbccm.com)

Rating: Restricted

Closing Price: USD 52.02

Price Target: Restricted

Implied All-in Return (%): Restricted

This security is restricted pursuant to RBC Capital Markets policy and, as a result, its continued inclusion in the *Top 30 Global Ideas* list has not been reviewed or confirmed as of the date hereof.



## American Tower Corporation (NYSE: AMT)

**RBC Capital Markets, LLC**  
Jonathan Atkin (Analyst) (415) 633-8589, [jonathan.atkin@rbccm.com](mailto:jonathan.atkin@rbccm.com)

## Investment summary

Our Outperform rating on AMT is based on the following factors: 1) highly predictable revenues due to long-term escalators and master-lease agreements, coupled with high revenue-to-cashflow conversion rates; 2) continued expectation that US gross new business activity should accelerate through the year and into 2023 – upside to activity levels and revenues in 2022 should be driven by Verizon C-band, DISH, and AT&T; 3) minimal balance sheet risks with steady path toward delevering toward the 3–5x range following the integration of recent acquisitions; and 4) an increasing dividend yield, following the full depreciation of older assets (e.g., acquired Alltel towers) and utilization of NOLs, could gradually broaden the company’s base of potential investors.

## Valuation

Our price target of \$282 is based on a blended ~27x forward P/AFFO multiple applying a ~29x multiple to US cash flows and a ~25x multiple to international cash flows. We believe our valuation parameters are appropriate given datacenter REIT multiples well into the 20x+ range, and the tower model's significantly lower capital intensity and greater operating leverage vs. datacenters. Additionally, tower operators have, on average, more stable cash flow and lower churn. In light of the implied upside vs. our price target, coupled with potential favorable acceleration catalysts around new spectrum deployment that could increase tenancies, we maintain our Outperform rating.

## Risks to rating and price target

Wireless network consolidation or widespread use of network sharing, femtocells, or other factors leading to lower-than-expected demand for tower sites represent the most significant potential risks to our price target and rating. Elevated India carrier consolidation churn for a longer period of time is a potential risk. We also see potential margin pressure from changes to ground and tenant lease-renewal terms and tax adjustments, although such factors are already largely incorporated into our existing projection horizon.


**Rating: Outperform**

**Price Target: USD 282.00**

**Closing Price: USD 258.40**


**Implied All-in Return (%): 11.3**

### Exhibit 11 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 12 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: [link](#)

## Anheuser-Busch InBev SA/NV (BRU: ABI; NYSE: BUD)

RBC Europe Limited

James Edwardes Jones (Analyst) +44 20 7002 2101, [james.edwardesjones@rbccm.com](mailto:james.edwardesjones@rbccm.com)
**Rating: Outperform**
**Price Target: EUR 65.00**
**Closing Price: EUR 51.54**
**Implied All-in Return (%): 27.6**

### Investment summary

AB InBev has underperformed the sector significantly over the last five years. Some of this has been due to elements out of its control, such as turbulent currency fluctuations in Latin America, but the organic performance has also been volatile. Both factors have also led to an unappealingly large debt pile.

Currencies remain the unknown but we think AB InBev's grip on the more controllable factors is tightening. The short-term performance has been more consistent, volume growth is improving and ABI's medium-term ambition of 4-8% EBITDA growth looks realistic to us. Its regional margins are underpinned by strong competitive positioning and there might even be some upside in South America. In addition, management seems to understand the negative implications of its debt load for shareholders and has hence made the decision to pass the interim dividend in both 2020 and 2021.

Adding to the long-term investment case are the potentially fruitful long-term prospects of AB InBev's digital platform: 'Bees' could drive further upside in our view. We think that there is (rightly) nothing in the share price to reflect this at the moment, but it's an interesting piece of optionality. We hold an Outperform rating for AB InBev.

### Valuation

We believe that consumer staples stocks lend themselves to a DCF valuation methodology owing to the relative strength and predictability of their cash flows together with, in some instances, a significant mismatch between capital expenditure and


depreciation charged through the profit and loss account, meaning that P&L-based valuation metrics (PE ratio, EV/ EBITDA ratio) can be misleading. We use a derivative of a traditional DCF calculation called adjusted present value (APV) whereby the business's operating cash flows are discounted at its cost of equity (8% in this instance) and tax shield at the cost of debt (3.0%). We assume a terminal growth rate of 2.5% per annum from 2035. Under these assumptions, we derive a fair value of €60 per share. Discounting the APV forward by a year at the cost of equity and adding in our dividend forecast for 2021 yields a 12-month price target of €65. Our price target and the implied return support our Outperform rating.

### Risks to rating and price target

Further inflation and a significant deterioration in consumer confidence and employment following Russia's invasion of Ukraine would be detrimental to sales and margins. A resurgence of COVID-19 and revival of on-trade closures and lockdown in response to the outbreak of COVID-19 poses a significant threat to AB InBev. On-trade closures would affect its ability to brand-build and manage working capital. Almost all of ABI's debt is in developed market currencies (principally US\$ and €). Any delay in paying down debt (for example, as a result of emerging market currency weakness) would be unhelpful for ABI's share price. The US is ABI's largest market and its largest mainstream brands have consistently lost market share; an acceleration in this market share loss, or slowdown in the US market overall, would not be good. ABI is heavily exposed to emerging markets, notably, Brazil, China, Colombia, Mexico and South Africa. A significant


deterioration in consumption or market share in these markets would be a downside risk.

### Exhibit 13 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 14 - Forward consensus EV/EBITDA history



Source: Factset

**Most recent industry note: [link](#)**

## Brookfield Asset Management Inc. (NYSE: BAM; TSX: BAM.A)

RBC Dominion Securities Inc.

Geoffrey Kwan, CFA (Analyst) (604) 257-7195, [geoffrey.kwan@rbccm.com](mailto:geoffrey.kwan@rbccm.com)

### Investment summary

**Why we rate Brookfield Asset Management shares**

**Outperform:** We think the combination of: 1) BAM's strong long-term investment track record; 2) significant liquidity available (US\$85B) to fund acquisitions and investments at potentially attractive prices in the current market environment and drive future NAV growth; and 3) a differentiated and diversified product shelf with demonstrated ability to fundraise and drive scale benefits could result in double-digit NAV growth over time. We continue to view the stock as a core holding.

**Potential catalysts include:** 1) Material value-surfacing monetizations or transactions; 2) strong fundraising activity positively impacting future Fee Related Earnings and carried interest growth; and 3) active acquisition/investment activity to drive future NAV growth.

### Valuation

Our 12-month price target is US\$68/share. We value BAM using an NAV methodology, which we think is appropriate given the diverse nature of BAM's assets. To arrive at our price target, we separately value: 1) BAM's asset management business by applying a 22x multiple to our blended 2023/2024 FRE forecast; and 2) we assume 25% growth in BAM's hard NAV (publicly traded subsidiaries, private investments, etc.). We also include a 0% premium-to-NAV assumption. Our lower premium-to-NAV assumption reflects a more uncertain macroeconomic backdrop. Our price target and implied return support our Outperform rating.

### Risks to rating and price target

Risks to rating and price target include: 1) economic downturn, particularly in real estate; 2) a sudden and/or significant increase in interest rates; and 3) sustained capital markets volatility.


**Rating: Outperform**

**Price Target: USD 68.00**

**Closing Price: USD 45.02**


**Implied All-in Return (%): 52.3**

Exhibit 15 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 16 - Forward consensus P/E history



Source: Factset

**Most recent company note:** [link](#)

## Canadian Natural Resources Limited (TSX: CNQ; NYSE: CNQ)

RBC Dominion Securities Inc.

Greg Pardy, CFA (Head of Global Energy Research) (416) 842-7848, [greg.pardy@rbccm.com](mailto:greg.pardy@rbccm.com)

### Investment summary

We rate the common shares of Canadian Natural Resources Outperform for the following reasons:

**Globally Distinguished.** Canadian Natural Resources' management committee structure and shareholder alignment are unique factors which distinguish the company globally. CNQ's long-life, low-decline portfolio—anchored by moderate sustaining capital—affords the company superior free cash flow generative power.

**Management Committee Structure.** CNQ does not have a CEO. Instead, the company is stewarded by a management committee consisting of 18 people. This group meets weekly and oversees all matters spanning marketing, finance, ESG, operations, and technology, amongst others. Murray Edwards, Executive Chairman, Tim McKay, President, and Mark Stainthorpe, CFO, are all key members of the committee.

**Impressive Shareholder Returns.** CNQ recently signaled that once its net debt falls to its \$8.0 billion floor, it is committed to incremental shareholder returns. CNQ's share buyback remains ring-fenced from acquisitions and strategic growth capital under a formulaic approach. More specifically, when net debt levels are below \$15 billion, the company will allocate 50% of its free cash flow after dividends and sustaining capital to share repurchases, with the balance (less strategic growth capital/acquisitions) earmarked for debt reduction. We peg CNQ's share repurchases at approximately \$5.9 billion in 2022, with net debt reduction of \$5.0 billion.

### Valuation

Our price target of \$85 per share reflects an equal weighting toward a multiple of 1.4x our NAV and an implied 2022E debt-adjusted cash flow multiple of 9.5x at mid-cycle commodity prices. The multiples we have chosen reflect CNQ's superior execution capability, long-life, low-decline asset base, and free cash flow generation potential. Our price target and implied return support our Outperform rating.

### Risks to rating and price target

The most significant risk to our price target and rating is unexpected changes in crude oil and natural gas prices. Specifically, to the extent that the COVID-19 pandemic and associated social distancing measures continue to negatively impact global oil demand, it may result in CNQ realizing lower-than-anticipated sales prices for its production volumes. Other risks include the impact of foreign exchange and government legislation as it relates to royalties, income taxes, and environmental policy.


Rating: Outperform

Price Target: CAD 85.00

Closing Price: CAD 71.85


Implied All-in Return (%): 22.5

### Exhibit 17 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 18 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: [link](#)

## Canadian Pacific Railway Limited (TSX: CP; NYSE: CP)

RBC Dominion Securities Inc.

Walter Spracklin, CFA (Analyst) (416) 842-7877, [walter.spracklin@rbccm.com](mailto:walter.spracklin@rbccm.com)

Rating: Outperform

Price Target: CAD 115.00

Closing Price: CAD 91.92

Implied All-in Return (%): 25.9

### Investment summary

Our positive view on CP centers on a best-in-class railroad on the cusp of a transformative acquisition that, if approved, should set the stage for significant growth and a material upward valuation re-rate. Key points:

#### CP's purchase of KSC significantly improves network reach.

The network advantage of the CP-KCS deal is the most compelling merit of the transaction in our view. The deal opens up new markets as well as gives CP a meaningful structural advantage versus peers. The transaction significantly increases the company's network reach from Vancouver to Saint John, and now via KCS, down to the ports of Lazaro Cardenas and Veracruz in Mexico. The new network connects six of the seven-largest metro regions in North America in a single-line connection, particularly between the Midwest US / Canada into the Gulf Coast / Mexico and a new third option between the Midwest US and Texas / Mexico.

**Diversification a big component of the value proposition in KCS deal.** Particularly favourable is the improvement in diversification that comes on both a business line and a geographic basis. Notable is the level of Merchandise exposure that KCS brings to CP, as well as the increased US and new Mexican revenue streams.

**US\$1B in potential synergies.** Of particular note is the revenue synergy opportunity (US\$820MM of the total) with expected share gains in Grain, Fertilizer, Intermodal, Auto, and Crude.

### Valuation

Our \$115 price target is based on applying a P/E multiple of 20x to our 2025 EPS estimate of \$6.73. Our 2025 EPS forecast reflects CP achieving full synergy run-rate on

the KSU acquisition in line with guidance provided when the deal was announced. The target multiple is a premium to peers, in our view warranted by CP's operations-focused management team as well as the increased network reach following the KSU acquisition. Our price target supports our Outperform rating.

### Risks to rating and price target

Key risks to our positive thesis relate to the acquisition of KSU. See below for further detail:


**Risk that merger does not get approved – we view as low.** Given the absence of any network overlap and the meaningfully higher weight in the revenue component of the forecast synergies, we see limited concern from a competition standpoint and a compelling case for a pro-competition argument. Nevertheless, the merger not getting approved is a potential risk.

**Mexico concession risk.** The two major rails in Mexico do not own their real estate and instead operate on concession from the Mexican government. The current concession expires in 2047; however, it is subject to an exclusivity review in 2027. Management teams at both entities are of the view that if CPKC provides a high-value service offering at a competitive price, there will be no need to make major changes to the concession arrangement.

**Integration risk.** We consider CP mgmt to be one of the top teams in North America and have strong confidence in the ability of this team to execute on the integration of this deal and achieve (or exceed) the targets announced. Moreover, we were encouraged by the concurrent announcement that CP's Board and CEO Keith Creel have agreed to contract amendments that


would see Mr. Creel lead the company out at least to 2026 (regardless of the deal going ahead or not). However, it is still possible that CP encounters unforeseen headwinds that could potentially impact forecasted synergies.

### Exhibit 19 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 20 - Forward consensus P/E history



Source: Factset

Most recent industry note: [link](#)



## ConocoPhillips (NYSE: COP)

RBC Capital Markets, LLC

Scott Hanold (Analyst) (512) 708-6354, [scott.hanold@rbccm.com](mailto:scott.hanold@rbccm.com)
**Rating: Outperform**
**Closing Price: USD 90.98**
**Price Target: USD 127.00**
**Implied All-in Return (%): 43.8**

### Investment summary

We believe COP shares should outperform large-cap E&P peers. COP has a returns-focused value proposition, a strong balance sheet, and peer-leading distributions. The company appears well positioned to maintain competitive FCF generation through various commodity price cycles. The scaled Permian position enhances the outlook with greater FCF generation, asset diversity, and development flexibility.

**Management has one of the clearest and most defined investment propositions.** COP was an early leader in committing and demonstrating high returns of capital back to shareholders. COP's priorities are: (1) sustain production and pay its dividend; (2) annual dividend growth; (3) A-rated balance sheet; (4) 30+% CFO total shareholder payout; and (5) disciplined investment for CFO expansion.

**A global and diverse asset base across the commodity spectrum mitigates unsystematic risk.** This also allows spending flexibility to deliver industry-leading returns through the commodity price and economic cycles.

**COP has a low Break-Even Point where it can fund its production maintenance capital and dividends at below \$40/bbl (WTI).** This is supported by a peer-leading base decline rate that results in a 35% less capital requirement to sustain production than peers.

**COP is the fifth-largest natural gas marketer in the US.** This creates opportunities to enhance transportation and sales mechanisms for margin improvement.

### COP adopted a Paris-aligned climate risk framework.

The long-term ambition for net-zero operational (Scopes 1 and 2) emissions is by 2050. There is a more defined medium-term target to reduce GHG emissions 40–50% by 2030.

### Valuation


Our \$127/share price target is derived from a combination of evaluating forward EBITDA multiples, and our Net Asset Value (NAV) and supports our Outperform rating. Our target reflects: 1) 4.5x multiple on our 2022 EBITDA estimate, inline with peer averages; and 2) a 68% premium to our \$76/share NAV, above the large cap 40% premium peer average due to peer-leading shareholder return commitment, solid FCF growth rates, a strong balance sheet, and asset diversity. Our NAV is a risk assessment of 3P reserves using the long-term RBC commodity price outlook of \$55/bbl (WTI), \$60/ bbl (Brent), and \$3.50/Mcf (HH).

### Risks to rating and price target

ConocoPhillips's returns-focused strategy is dependent on strong margins, cost control, and execution. Industry inflation or unforeseen cost overruns could limit the company's ability to deliver significant returns to shareholders and negatively impact the share price.


Regulatory changes could adversely impact the company's development opportunities and economics. COP has federal acreage on certain core assets in both the Permian Basin and Alaska that could be impacted by regulatory changes.

### Exhibit 21 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 22 - Forward consensus EV/EBITDA history



Source: Factset

**Most recent company note:** [link](#)

## CrowdStrike Holdings, Inc. (NASDAQ: CRWD)

RBC Capital Markets, LLC

Matthew Hedberg (Analyst) (612) 313-1293, [matthew.hedberg@rbccm.com](mailto:matthew.hedberg@rbccm.com)

Rating: Outperform

Closing Price: USD 179.25

Price Target: USD 232.00

Implied All-in Return (%): 29.4

### Investment summary

#### High-level thesis of CrowdStrike

CrowdStrike was founded in 2011 with a mission of reinventing security for the cloud era. Co-founder George Kurtz previously worked at a gen-1 AV endpoint vendor and was motivated to build CrowdStrike after realizing that legacy security technology was incapable of protecting customers against modern attacks within a hybrid-cloud architecture.

The company developed a differentiated cloud-native security platform that leverages its lightweight intelligent agent and Threat Graph database across a multi-module portfolio of solutions. The company and its customers benefit from the network effect, as each additional endpoint added to the platform expands the crowd-sourced database, which in turn improves the quality of the algorithms.

We view CrowdStrike as a prime land-and-expand model benefiting from SaaS delivery and ability to rapidly add more modules with no extra configuration or consulting needed. The long-term power of the install base should lead to strong net expansion rates as the company cross-sells additional seats (endpoints) and modules.

**Potential catalysts include:** 1) ability to maintain net expansion rates by selling additional products into its growing customer base and maintaining low churn rates; 2) new product introduction and/or traction from recently introduced modules; specifically Cloud Workload protection; 3) accelerated customer additions leveraging its multi-pronged, go-to-market approach; 4) accelerated share-shift from legacy vendors; and 5) faster-than-expected progression toward profitability driven by top-line success.


#### Valuation

To derive our \$232 price target, we apply an 18.5x EV/S multiple to CY/23E revenue of \$2,975.6 million, which is a premium to leading growth security peers, in our view reasonable given that our growth outlook is likely biased higher. Our price target supports an Outperform rating.

#### Risks to rating and price target


Risks to rating and price target include: 1) CrowdStrike operates in a market with competition from larger legacy competitors, like Symantec, as well as newer entrants; 2) potential pricing pressure given the crowded nature of the market; 3) CrowdStrike operates a land-and-expand model; failure to retain existing customers could be a detriment; 4) CrowdStrike has experienced rapid growth; failure to manage growth/expectations could cause operational challenges; and 5) COVID-19 could impact company operations or customer demand.

### Exhibit 23 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 24 - Forward consensus EV/sales history



Source: Factset

Most recent company note: [link](#)

## DuPont de Nemours, Inc. (NYSE: DD)

RBC Capital Markets, LLC

Arun Viswanathan, CFA (Analyst) (212) 301-1611, [arun.viswanathan@rbccm.com](mailto:arun.viswanathan@rbccm.com)
**Rating: Outperform**
**Closing Price: USD 54.75**
**Price Target: USD 84.00**
**Implied All-in Return (%): 55.6**

### Investment summary

**Factors that support our Outperform rating.** Early cycle recovery in China will likely help DD achieve a faster recovery than peers, along with cost-action plans to help incremental margins. Additionally, we believe the N&B sale to IFF was a major first step in DD's portfolio transformation plan and DD still has further portfolio transformation plans in place. Lastly, the PFOA case brought by CC has now been dismissed, and we believe a settlement will help DD move past the PFOA uncertainty overhang.

**Multiple expansion opportunity as a multi-industrial company.** Given that DuPont's valuation multiples could increase 2–3x, should DuPont successfully market itself as a multi-industrial company, we believe valuation multiples could move higher. DuPont notes that when comparing against other multi-industrial companies (MMM, HON, and ITW), DuPont provides similar-in-class benchmarks.

**Further divestment plans post COVID-19.** Considering Chairman Ed Breen's successful divestment cases at Tyco when he was CEO of that company, we believe DuPont will continue assessing its portfolio to divest unaligned businesses in order to deliver shareholder value.


### Valuation

We value DuPont on a forward EV/EBITDA basis using 2023E. We apply a 14x multiple to our 2023E EBITDA of \$3.780B (which includes recent M&A and divestitures but not Rogers) to arrive at a price target of \$84/share. Despite the raw materials pricing headwind, given the pending divestment of lower multiple business, portfolio transformations and buybacks, we believe DD should trade at the mid-to-high end of its historical 9–15x multiple range. Our price target supports our Outperform rating.

### Risks to rating and price target


Risks to rating and price target include: 1) slower than expected cycle recovery in China and North America; 2) synergy/integration challenges; 3) further delays or failure to optimize spin strategy; and 4) further demand deterioration from COVID-19 impact.

### Exhibit 25 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 26 - Forward consensus P/E history



Source: Factset

**Most recent company note: [link](#)**

## Intact Financial Corporation (TSX: IFC)

RBC Dominion Securities Inc.

Geoffrey Kwan, CFA (Analyst) (604) 257-7195, [geoffrey.kwan@rbccm.com](mailto:geoffrey.kwan@rbccm.com)
**Rating: Outperform**
**Closing Price: CAD 182.67**
**Price Target: CAD 216.00**
**Implied All-in Return (%): 20.4**

### Investment summary

**Why we rate IFC Outperform:** We believe IFC's risk-reward is particularly attractive, reflecting strong defensive attributes coupled with: 1) positive fundamentals within all of its business segments; 2) significant accretion potential from the acquisition of RSA; and 3) further valuation upside if IFC de-risks the RSA acquisition (e.g., further divestitures, asset swaps). We believe our 12-month price target and implied total return support our Outperform rating.

**Potential catalysts include:** 1) IFC de-risking the RSA acquisition (e.g., divestitures, asset swaps); 2) improving combined ratios, especially in Personal Auto; 3) accretive acquisitions; and 4) better-than-expected premium growth.


### Valuation

Our 12-month price target of \$216/share is based on applying a 2.5x P/BV multiple to our Q2/23 BVPS forecast of \$86.36. IFC's shares have traded at an average P/BV multiple of 2.2x over the last 10 years and currently trade at a slight discount to the 10-year average. We think that our target multiple is supported by our operating ROE and BVPS forecasts. Our price target and implied total return support our Outperform rating.

### Risks to rating and price target


Risks to rating and price target include: 1) negative regulatory developments; 2) significant increase in catastrophes; 3) deteriorating combined ratios; and 4) integration/execution risks regarding the recent acquisition of RSA.

### Exhibit 27 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 28 - Forward consensus P/E history



Source: Factset

**Most recent company note: [link](#)**

## Lonza Group AG (SWX: LONN)

RBC Europe Limited

Charles Weston, CFA (Analyst) +44 20 7429 8425, [charles.weston@rbccm.com](mailto:charles.weston@rbccm.com)

Rating: Outperform

Closing Price: CHF 524.80

Price Target: CHF 650.00

Implied All-in Return (%): 24.5

### Investment summary

**Market trends to remain robust.** The pharma market is growing at 6-7% pa and ongoing trends towards manufacturing outsourcing and onshoring will drive the CDMO market growth into the high single digits, in our view, with COVID vaccines adding incremental growth in 2021/22.

### Lonza is positioned at the premium end of the market.

Lonza is the largest and one of the most profitable CDMOs globally, deriving almost half of its revenues from biologics, which we expect to grow faster than the overall market, and 10% from cell and gene therapy, which could grow in the high teens pa, in our view.

### Enhanced focus and transparency complemented by a strong balance sheet.

Having divested its Water Care business in 2019 and its Specialty Ingredients division in 2021, Lonza is focused on pharma manufacturing, and the divestments have left the balance sheet with CHF1.6bn of net cash (end-'21), providing for ample strategic flexibility to invest. The company is transitioning to a new divisional reporting structure and has provided granular long-term guidance.

**Financials.** We forecast that Lonza will average 10-11% revenue growth pa, with 1-3ppts of additional growth in 2022 from the Moderna COVID vaccine. We think an improvement in group margin of c.80bps pa is achievable from divisional improvements, particularly in the CGT division, and we see operating cash conversion as remaining very strong (90%-plus) (before substantial capex investments at c.3x depreciation).

### Valuation

The median 'EEG' of the larger Western CDMO peers is 1.6x (i.e., EV/EBITDA divided by EBITDA growth), implying 21x 2023E EV/EBITDA, which leads to our 12-18-month price target of CHF650. This is roughly equivalent to our DCF calculation at a cost of equity of 6.5% and terminal growth of 3.0%. This price target supports our Outperform rating.

### Risks to rating and price target


**Overcapacity.** Pharma, CDMO, CRO and VC organisations are investing heavily into biologic production, which could lead to price competition. Our analysis suggests that this is unlikely to be an issue in the foreseeable future, but it remains a perceived risk.

**IT hack.** Malicious actors have targeted the healthcare supply chain, including hacking Lonza's peer Siegfried. Lonza could also become a target, which would potentially result in the shutdown of manufacturing sites.

**COVID vaccine revenues fall away.** Having guided to CHF110m revenue in 2021 from the Moderna vaccine, it then doubled capacity at some of its plants for the product. We model CHF220 revenue for 2022, and assume half is lost in 2023, although confidence around this assumption is low.


**Additional large partnerships.** Should Lonza sign new manufacturing agreements for large products, there could be upside to forecasts and to stock sentiment.

### Exhibit 29 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 30 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: [link](#)



## M&T Bank Corporation (NYSE: MTB)

RBC Capital Markets, LLC

Gerard Cassidy, CFA (Analyst) (207) 780-1554, [gerard.cassidy@rbccm.com](mailto:gerard.cassidy@rbccm.com)
**Rating: Outperform**
**Closing Price: USD 159.71**
**Price Target: USD 190.00**
**Implied All-in Return (%): 22.0**

### Investment summary

We rate MTB shares Outperform for the following key reasons:

**Best-in-class management team:** M&T Bank Corporation's management team has led the company through more than 15 years of consecutive quarters of profitability.

**People's United Financial, Inc. (PBCT) acquisition:** We anticipate M&T's acquisition of PBCT will have modest tangible book value dilution but combined with long-term solid earnings accretion, it should drive long-term shareholder value. Fully phased-in cost savings are estimated at \$330 million and the internal rate of return on the transaction is an estimated 18%. We expect MTB to meet or exceed its targets in this transaction.

**Allocation of capital:** We continue to believe the company is one of the best managers of capital among the top 20 banks. M&T's estimated Common Equity Tier 1 (CET1) ratio was 11.6% in 1Q22 versus 11.4% in 4Q21. Following the close of the PBCT acquisition the CET1 ratio will drop to just over 11.0%. M&T announced in January an \$800 million stock repurchase program. The repurchase program was put on hold until the closing of the PBCT acquisition, but is expected to begin shortly. In addition, MTB disclosed a target CET1 ratio of 10.5% by 2022 year-end which will largely be achieved through the stock buyback, in our view.

**Strong balance sheet:** M&T proved during the last recession and financial crisis that it has a very strong balance sheet. M&T was one of only two of the top 20 banks that did not cut or eliminate its dividends over the last 15 years.

**Superior underwriting standards:** The company's credit metrics, nonperforming asset (NPA), and net charge-off (NCO) ratios have consistently been below its peer group for the past 10 years.

**Low-cost provider of bank products:** M&T recognizes that it operates in a commodity business and therefore strives to be the low-cost provider of bank products in its markets. Its efficiency ratio (total operating expenses divided by total revenues) has consistently been the lowest among the top 20 banks.

**Long-term investors rewarded:** MTB's stock price has outperformed the S&P 500 and the S&P 500 bank indices in each of the last 10- and 20-year time periods. The outperformance can be attributed to the company's focus on growing tangible book value and dividends per share.

### Valuation


Our price target of \$190 is 13.1x our 2022 EPS estimate, 1.52x 1Q22 book value, and 2.13x 1Q22 tangible book value. Our price target primarily reflects our profitability and risk assessment of the company relative to a peer group of similar companies, as well as current market concerns over the impact from COVID-19. This multiple is consistent with the highest-quality banks in the peer group. We believe the premium is warranted by the company's consistent fundamental performance, strong capital position, and clean asset quality. Our price target and implied return support an Outperform rating.

### Risks to rating and price target

We believe aggressive monetary tightening by the Federal Reserve which results in driving the US economy


into a recession in 2022 is the key risk for the company, our rating and price target. A recession would bring on elevated levels of credit losses which would depress earnings.

### Exhibit 31 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 32 - Forward consensus P/E history



Source: Factset

**Most recent company note:** [link](#)

**Mastercard Inc. (NYSE: MA)****RBC Capital Markets, LLC**

**Daniel R. Perlin, CFA (Analyst) (410) 625-6130, [daniel.perlin@rbccm.com](mailto:daniel.perlin@rbccm.com)**

## Investment summary

We believe MA is a core long-term holding and an “indexed” way to play payments and benefit from three global secular mega-trends including 1) global consumption, 2) global digitization of payments, and 3) global innovation, which is creating new payment flows.

We note that ~67% of its TAM is from new payment flows, beyond the classic cash to card conversion, while we forecast service revenues to grow 2x the carded-market and are heavily focused on cyber-intelligence/security and data analytics/services, both long-term secular themes.

Assuming a more normalized macro spending environment, which includes a resumption of travel spending, we estimate ~\$1B of incremental revenues are embedded in the model.

## Valuation

Our price target of \$417 is 33x our CY23 EPS estimate, generally in line with its historical average. Underlying our estimates are expectations for: 1) near-term pressure before a rebound to double-digit growth in purchase volumes, with modest pricing and secular growth; 2) double-digit increases in transaction revenues; 3) near-term pressure on cross-border revenue growth; and 4) relatively flat client incentives as a percentage of gross revenues. Our price target supports our Outperform rating.

## Risks to rating and price target

A slowdown in payment volumes and cross-border travel (from such things as the current pandemic), increased regulatory scrutiny or a pushback from large financial institutions on pricing could impede our price target and rating.


**Rating: Outperform**

**Price Target: USD 417.00**

**Closing Price: USD 318.24**


**Implied All-in Return (%): 31.7**

### Exhibit 33 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 34 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)

## The Mosaic Company (NYSE: MOS)

RBC Dominion Securities Inc.

Andrew D. Wong (Analyst) (416) 842-7830, [andrew.d.wong@rbccm.com](mailto:andrew.d.wong@rbccm.com)

**Rating: Outperform**

**Price Target: USD 85.00**

**Closing Price: USD 46.92**

**Implied All-in Return (%): 82.4**

### Investment summary

Mosaic is a leading producer of potash and phosphate fertilizers and also has a production and distribution business in Brazil. The company has embarked on several transformation initiatives in the past several years that have resulted in improved operational efficiency, lower costs, and rising cash flow.

### Potential catalysts

Mosaic is operating at 10.8Mt potash operational capacity after successfully ramping up Esterhazy K3 and re-starting Colonsay. The company may increase operational capacity by an additional 1.5Mt by H2/23 by bringing on the second Colonsay and further debottlenecking at Esterhazy K3.

The company expects to realize significant cost savings through 2023 with several company initiatives including the ramp-up of Esterhazy K3 mine, introduction of new advanced mining technologies (remote mining, automation), transformation initiatives at the Brazil Fertilizantes business, and growing value-add premium products.

We expect Mosaic to generate significant free cash flow due to strong prices, higher volumes, lower costs, and lower capex. We estimate \$7.5B excess FCF through 2024, which we think will be largely used for capital return to shareholders.

Mosaic acquired Vale's Brazil-based phosphate and potash assets in 2018 and realized run-rate synergies of >\$300M by end-2019. The company is targeting an additional \$200M EBITDA benefit from ongoing business transformation efforts by end-2022.


### Valuation

We derive our \$85 price target by attributing an equal weighting to our SOTP EV/EBITDA and DCF valuation. Our SOTP EV/EBITDA analysis applies a 7.0x multiple to 2025 EBITDA estimates for the Potash, Phosphate, and Fertilizantes segments. These multiples are in line with the multiples used to value Mosaic's peers. Our DCF analysis uses a 9% real discount rate. The implied return to our price target supports our Outperform rating.

### Risks to rating and price target


Risks to rating and price target include: 1) unpredictable weather events in North America or international markets can have an adverse impact on demand for agricultural inputs; 2) Mosaic has operations in the US, Canada, and other foreign countries, so currency fluctuations can have an impact on earnings; 3) nutrient prices can be volatile and can have a significant impact on Mosaic's profitability; and 4) Mosaic uses natural gas, sulphur, and other inputs in producing its fertilizer products, so changes in the prices of these inputs can have an impact on its earnings.

### Exhibit 35 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 36 - Forward consensus EV/EBITDA history



Source: Bloomberg, RBC Capital Markets

**Most recent company note:** [link](#)

## Palo Alto Networks, Inc. (NYSE: PANW)

RBC Capital Markets, LLC

Matthew Hedberg (Analyst) (612) 313-1293, [matthew.hedberg@rbccm.com](mailto:matthew.hedberg@rbccm.com)
**Rating: Outperform**
**Closing Price: USD 508.25**
**Price Target: USD 680.00**
**Implied All-in Return (%): 33.8**

### Investment summary

Palo Alto Networks is a provider of next-generation network and endpoint security. The company should be able to grow into a growing network and endpoint security market by expanding within its customer base while increasing its reach to new customers through a larger portfolio, geographical expansion, and share shift. We view Palo Alto as well positioned to benefit from an increasingly complex security and threat landscape and as an industry leader in security.

**Growth drivers include:** 1) above-market growth opportunity by taking share from legacy security vendors; 2) land, expand, and retain strategy for maximizing value from existing install base; 3) potential market gains from a disruptive subscription business; 4) international growth opportunities; 5) opportunity for margin expansion through economies of scale; and 6) benefits from the increased focus on data security due to ongoing breaches and increased regulation.


### Valuation

Our \$680 price target assumes that shares trade at an EV/FCF multiple of 35x our CY/23 estimate, a slight premium to contracted LC peers. Our price target and multiple reflect our confidence in the momentum of next-gen billings and durability of network security given improved consistency as well as new visibility provided for the strategic outlook. On an EV/recurring revenue basis, our price target reflects 11.5x our CY/23 estimate, in line with similarly growing peers. The implied return to our price target supports our Outperform rating.

### Risks to rating and price target


Risks to rating and price target include: 1) improvements around the product line and impact from sales incentives to drive product growth are taking longer than expected; 2) the macro environment remains uncertain; although the security market remains robust, a slowdown in global activity could hinder results; 3) dependency on channel partners is significant and concentrated among several large global distributors; 4) Palo Alto could face increased competition as it continues to take share either from legacy providers or new entrants to the security market; and 5) the company could encounter operational difficulties as it attempts to continue to rapidly increase in scale.

### Exhibit 37 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 38 - Forward consensus EV/sales history



Source: Factset

**Most recent company note: [link](#)**

## R1 RCM Holdco Inc. (NASDAQ: RCM)

RBC Capital Markets, LLC

Sean Dodge, CFA (Analyst) (615) 372-1322, [sean.dodge@rbccm.com](mailto:sean.dodge@rbccm.com)

Rating: Outperform

Price Target: USD 35.00

Closing Price: USD 21.97

Implied All-in Return (%): 59.3

### Investment summary

R1 RCM, Inc. helps both acute-care and ambulatory providers better manage their revenue cycles—its offerings range from software modules that clients can install and run themselves to full outsourcing. RCM outsourcers, like R1, leverage their own operational expertise and shared resources to drive efficiencies and economies of scale. Healthcare providers benefit by offloading these increasingly expensive, non-core functions, freeing up time to focus on delivering higher-quality patient care. Increasingly complex regulations and rising costs are driving increased demand for these services. Notably, findings from our recent survey of hospital executives show 32% of respondents said they are planning to outsource more of their RCM processes over the next 3 years.

Currently, the majority of R1's revenue comes from its largest customer, Ascension. The company has spent the last few years onboarding Ascension's RCM operations, and in the process, has enhanced its product offering and operational expertise—both helping pave the way for future expansion. Over the course of FY19, R1 signed three new outsourcing contracts (representing over \$4B of NPR) and added an additional \$5B in FY20, demonstrating its ability to commercialize its offerings outside of its core client base.

### Potential catalysts

**More contract/NPR Wins.** As R1 continues to add new clients and contracts, it both helps further diversify its base and provides additional proof-points it is able to

commercialize its offerings beyond its core customers. Management did recently announce it is expanding its annual new NPR deployment capacity to \$9B, from \$5B previously, signaling its increasing confidence in both the LT demand environment as well as its relative competitiveness.

**Improving EBITDA margin via tech investments.** Management generated approximately \$20M of EBITDA in 2020 from implementing robotic process automation to automate redundant tasks. The company continues to invest in RPA and other technologies and expects them to contribute another incremental \$25M+ in 2022. Further demonstrating these solutions are working and generating savings could provide a lift to both margins and share price.

### Valuation


Compared to its HCIT and outsourced services peers, RCM: 1) features a more stable, defensive revenue and earnings stream; 2) should grow EBITDA/EPS at a rate nearly 2x the group average over the next 3 years; and 3) given the contracts/NPR it has recently signed, has better forward visibility on growth. For these reasons, we believe RCM should trade at a premium to the group average. Our \$35 price target is based on RCM trading at 26x our 2023 EBITDA estimate. Our valuation work and price target support our Outperform rating.

### Risks to rating and price target

Risks to our Outperform rating and price target include significant customer concentration, prolonged impact from the COVID-19 pandemic, competition, product


concentration, and a lingering negative reputation from prior lawsuits.

### Exhibit 39 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 40 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: [link](#)



## S&P Global Inc. (NYSE: SPGI)

RBC Capital Markets, LLC

Ashish Sabadra (Analyst) (415) 633-8659, [ashish.sabadra@rbccm.com](mailto:ashish.sabadra@rbccm.com)

Rating: Outperform

Closing Price: USD 343.33

Price Target: USD 434.00

Implied All-in Return (%): 27.3

### Investment summary

We believe that the strategic INFO acquisition should accelerate the normalized revenue growth profile and deliver double-digit earnings growth driven by upside to revenue and cost synergies. Complementary data assets powered by Cloud and AI/ML should enable predictive actionable insights from disparate data assets and distribution at scale. Importantly, the transformative acquisition should propel SPGI's ESG offerings and private company offerings. Separately, SPGI guided to \$12bn+ of share repurchases in FY22, along with near-term cost takeout initiatives that could drive upside to FY23 EPS.


### Valuation

Our price target of \$434, which supports our Outperform rating, is based on ~28x our FY23E EPS of \$15.50, in line with the 2-year average, as the diversified business model, accelerated cost takeout, and large share repurchase help to limit downside risk to earnings posed by recent weakness in credit issuance.

### Risks to rating and price target


Risks to rating and price target include: 1) a significant decline in credit issuance; 2) increased competition for market data; 3) slowdown in demand for Platts; 4) challenges in integrating acquisitions; and 5) decline in AUM linked to SPGI indices.

### Exhibit 41 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 42 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)

## Shell PLC (LSE: SHEL; NYSE: SHEL)

RBC Europe Limited

Biraj Borkhataria, CFA (Analyst) +44 20 7029 7556, [biraj.borkhataria@rbccm.com](mailto:biraj.borkhataria@rbccm.com)

Rating: Outperform

Closing Price: GBp 2,203.00

Price Target: GBp 3,000.00

Implied All-in Return (%): 39.9

### Investment summary

Shell is our preferred Integrated Energy Major in 2022.

Key reasons for our positive stance:

**Cash flow machine.** On our bullish commodity forecast, Shell generates significant amounts of cash, supported by its oil leverage and #1 presence in an extremely strong LNG market.

**Re-rating warranted?** Shell generates a superior FCF yield on average relative to the sector over 2022-25E but trades at a discount on a DACF multiple basis. We think increasing shareholder returns this year should help drive a re-rating, while continued de-leveraging sets Shell up to become a more stable business through the cycle.

**Sum of the Parts.** Shell has three franchise businesses within the group, all of which are #1 in their respective areas, which we believe is not reflected in the share price today. Activist investors recently engaged with the company and this could help unlock value.


### Valuation

We value SHEL based on a 2023E EV/DACF multiple of 6.5x for its core business along with a build-up of its low carbon portfolio, adjusted for debt. This leads to a price target of 3,000p, which supports our Outperform rating.


### Risks to rating and price target

Risks to our price target and rating include: overcapacity in LNG as Shell is involved in multiple growth projects whilst also being the largest supplier of LNG globally; sustained weakness in US gas prices constraining profitability of gas drilling in the US; security risk in key areas in the Middle East and North Africa where Shell is highly exposed; and fiscal risk and uncertainty surrounding regulation in the oil & gas industry. In general, all international integrated oil companies are exposed to resource price fluctuations, political/security risk, execution risk, and environmental/permitting risks.

### Exhibit 43 - Share performance and RBC valuation



### Exhibit 44 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)

## Siemens AG (XETRA: SIE)

RBC Europe Limited

Mark Fielding (Analyst) +44 20 7002 2128, [mark.fielding@rbccm.com](mailto:mark.fielding@rbccm.com)

Rating: Outperform

Price Target: EUR 175.00

Closing Price: EUR 97.60

Implied All-in Return (%): 82.9

### Investment summary

Siemens has become a simpler business over the last 10-15 years, but all the change has made past performance hard to understand. We have analysed in detail the underlying performance of the continuing "new" Siemens over the last 15 years. This shows above sector growth and margin progress across the cycle, and one of the most resilient companies in downturn phases. This does not tally with a continued sector P/E discount of 15-20%.

**Outperforming the sector through the cycle:** Our analysis shows that "new" Siemens has not just outgrown "old" Siemens since 2006, but also the sector. It has delivered a 2006-21 sales CAGR of +4.2% vs the sector +3.6% and old Siemens +2.9%. And profit margins have risen by ~500bps such that the Industrial business is slightly better than the sector average. This supports our base case for ongoing growth in the 5-7% target range and further margin expansion.

**And "new" Siemens is resilient in downturn phases:** While our base case is for further positive progress, given wider geo-political concerns we also considered recessionary risks. Our modeling of the new Siemens industrial business shows it is much less cyclical than average for our coverage. Over the past three industrial downturn phases since 2007 its sales have never fallen by more than -2% and its margins by less than 100bps. This is versus a sector average -7% sales fall and 160bps margin decline.

### Valuation

We value Siemens on a target P/E of 20x 23E, which is slightly above our sector average given our analysis shows Siemens continuing business as a through cycle outperformer versus the sector from an operational standpoint. It gives a valuation of €175 per share. P/E is a fair multiple to use in our view given the complicated nature of the group and its underlying net debt / EBITDA being at ~1x in line with the sector average. Our price target supports our Outperform rating on the stock.

### Risks to rating and price target


**Covid-19 impact:** The business is now recovering, but any renewed waves could be a further negative. Short-cycle businesses (DI and SI) have seen challenges, most notably in China, Germany and Italy, in the automotive and machine-building sectors. Near-term site access at Mobility continues to be impacted.

**Cost flexibility:** Siemens' size, complexity and board-level representation from labour unions mean that it has historically not been very agile with its cost basis. Siemens has been changing this, but it remains a factor.

**Sector de-rating:** Further concerns of a deep recession could precipitate a general sell-off and de-rating in the industrials sector, thus affecting Siemens' valuation.


**Siemens could suffer indiscriminate buying/selling pressure:** Siemens is a highly liquid proxy for industrial Europe and could be bought or sold by portfolio managers wanting to increase or reduce European industrial or European cyclical exposure. The share is also a major component of Germany's DAX Index.

### Exhibit 45 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 46 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)

## Stericycle, Inc. (NASDAQ: SRCL)

RBC Capital Markets, LLC

Sean Dodge, CFA (Analyst) (615) 372-1322, [sean.dodge@rbccm.com](mailto:sean.dodge@rbccm.com)

Rating: Outperform

Price Target: USD 82.00

Closing Price: USD 44.37

Implied All-in Return (%): 84.8

### Investment summary

The last 4–5 years have been rough for what once was a very consistent growing company and high-flying stock. Beginning in 3Q15, SRCL was hit by a confluence of challenging headwinds, and as some abated, others piled on. The impact on the stock has been significant—from its 5-year high to low, shares were off more than 75%. We believe things are changing, though, and we see more evidence that SRCL's turnaround is gaining traction. An entirely new management team (led by ex-UPS exec Cindy Miller) has made quick progress re-simplifying the business (i.e., divesting non-core assets) and overhauling operations, and the implementation of a global ERP system is now under way. Shares are up from recent lows, but valuation still looks attractive to us, relative to both peers and its longer-term historical trading range. We believe investors want to see: (1) continued execution on new operational/efficiency initiatives; (2) evidence that SRCL can adjust its pricing to offset the growing inflationary pressures; and (3) a successful implementation of its new ERP system. As organic revenue growth resumes, margins lift, and the balance sheet continues to de-lever, we believe the benefits of SRCL's anti-cyclical model should shine through and its multiple should grind higher.

### Potential catalysts

**Continued Execution on Operational Efficiency and Cost-Reduction Initiatives.** CEO Cindy Miller has very quickly put her operations background/expertise to use, working to enhance the quality of SRCL's revenue base, improving its commercialization efforts, and streamlining its operations. We believe the recent return of positive organic growth and improving margins reflect this. There is still a long way to go, however.

Continued execution on both fronts should continue pushing the stock higher.

**Restarting Tuck-In M&A.** After completing 10 divestitures, which eliminated a majority of the more volatile non-core parts of SRCL's portfolio, the company recently completed its first acquisition in three years, of a Midwest-based medwaste company. With management also now having successfully stabilized the company, we view tuck-in M&A as a very effective and accretive way to grow revenue and profitability, and we see the resumption of its M&A efforts as an encouraging sign that SRCL is (re)entering the next phase of growth.


### Valuation

Our \$82 price target reflects our confidence that the near-term hiccups related to the ERP implementation will be short-lived. Our valuation is based on a 31x multiple of our 2023 EPS estimate, which is in line with the peer average. Our price target supports an Outperform rating.

### Risks to rating and price target


Risks include increasing competition and pricing pressures across its core markets, disruptions and/or elevated costs stemming from the COVID-19 pandemic, significant international exposure, an upcoming ERP implementation, a levered balance sheet, and fluctuating paper prices.

### Exhibit 47 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 48 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)

## TELUS Corporation (TSX: T; NYSE: TU)

RBC Dominion Securities Inc.

Drew McReynolds , CFA, CA, CPA (Analyst) (416) 842-3805, [drew.mcreeynolds@rbccm.com](mailto:drew.mcreeynolds@rbccm.com)

**Rating: Outperform**

**Price Target: CAD 36.00**

**Closing Price: CAD 28.58**

**Implied All-in Return (%): 30.6**

### Investment summary

We view 2022 guidance in February 2022 as a pivotal turning point for TELUS as the company transitions into a new post-FTTH build / 5G phase. While there is no finish line as TELUS positions itself to now capture 5G opportunities, we do believe the company is emerging in 2022 and 2023 with a distinctively different financial and operational profile relative to most global telecom peers. As FTTH coverage reaches ~85%-90% of the targeted broadband footprint by the end of 2022, enhanced capex flexibility should enable TELUS to capitalize on 5G without meaningful capital constraints, opportunity costs, or FCF impairment. Longer term, under certain operational and regulatory conditions, we see strong strategic and financial rationale for TELUS to explore a transformational re-organization that can fully unlock the value of the company's core infrastructure assets and core technology assets.

**Potential catalysts for the stock include:** (i) greater-than-expected wireline subscriber traction driven by FTTH expansion; (ii) better-than-expected efficiencies and operating leverage resulting in higher margins; (iii) an easing of Alberta headwinds resulting in improved business market performance; (iv) stronger-than-expected improvement in wireless ARPU growth; and (v) greater-than-expected step-down in consolidated capex intensity over the medium term.


### Valuation

The implied total return to our \$36 price target supports our Outperform rating. To derive our target, we take the average of three approaches: (i) applying a 22.5x multiple to our blended two-year forward adjusted EPS estimates; (ii) applying a target EV/EBITDA multiple of 8.75x to our blended two-year forward EBITDA estimates for TELUS Technology Solutions and factoring in our one-year target for TELUS International; and (iii) discounted FCF through 2030E factoring in a WACC of 8.0% and a terminal growth rate of 1.75%. We believe our target multiples are consistent with the company's growth and risk profile relative to Canadian peers, and a low interest rate environment.

### Risks to rating and price target


Risks to the shares reaching our one-year price target and Outperform rating are: (i) unforeseen direct and indirect COVID-19 impacts; (ii) a sustained increase in wireless competition and/or unexpected change in regulation resulting in higher churn and/or accelerated declines in postpaid ARPU; (iii) inability to realize additional cost savings to improve wireline margins; (iv) higher-than-forecast spectrum outlays; (v) emergence of irrational pricing in residential telephony, television, and/or Internet; and/or (vi) higher interest rates and/or a reversal in fund flows out of the sector.

### Exhibit 49 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 50 - Forward consensus P/E history



Source: Factset

**Most recent company note:** [link](#)

## TransDigm Group Inc. (NYSE: TDG)

RBC Capital Markets, LLC

Ken Herbert (Analyst) (415) 633-8583, [ken.herbert@rbccm.com](mailto:ken.herbert@rbccm.com)

Rating: Outperform

Closing Price: USD 541.69

Price Target: USD 750.00

Implied All-in Return (%): 38.5

### Investment summary

TDG is primarily a play on the commercial AM recovery, with optionality from capital allocation (M&A upside and capital return to shareholders). The company is known for its ability to successfully integrate acquisitions, so investors are generally supportive of M&A activity, even for larger transactions. For example, the acceleration on the EBITDA after the Esterline Technologies acquisition was faster than expected.

We believe that if TDG were to complete a larger acquisition, it would be a positive catalyst for the stock. There could be incremental acquisition opportunities if more diversified industrial companies look to break up, similar to GE's strategy. However, TDG is also focused on smaller transactions as it looks to build its EBITDA base.

In fiscal 2Q22 commercial AM growth was 46% (~10% sequentially). The company highlighted a book-to-bill of over 1x in the quarter. Continued strength in the commercial AM is the most important factor for continued EBITDA upside for TDG, and we like TDG for its AM exposure and leverage. The aviation fundamentals remain sound as airlines look to add capacity in calendar 2022. TDG would benefit from the volume increase, but also from an aggressive approach to pricing in the commercial AM. TDG also benefits from its exposure to business jets and helicopters (~15% of the commercial AM revenues) and cargo aircraft.

TDG has also created value through its aggressive use of leverage. The company has benefited from low interest rates, and it is comfortable with a balance sheet that typically ranges between 5x and 7x leveraged on a TTM EBITDA basis. The fear of rising rates can be a headwind for sentiment on the stock, but over the last 15 years this has not turned out to be a material risk for the company. The

company currently has ~85% of debt exposure fixed for the next few years.

### Valuation


Our \$750 price target is based on 32x P/E and ~21x EV/EBITDA on our 2023E. We believe multiples above the historical range are appropriate considering the expected acceleration in commercial AM growth in 2022 and the capital allocation optionality. We believe the stock provides investors exposure to the commercial AM recovery, with upside potential from capital allocation and margin expansion. In our view, our \$750 price target justifies an Outperform rating.

### Risks to rating and price target

Risks to rating and price target include: airline and lessor financial health and their ability to take delivery of new aircraft; airline spending trends on the maintenance, repair, and overhaul of aircraft; the pace of the air travel recovery and the impact of COVID-19 variants on business and leisure air travel; airline and aircraft part distributor inventory levels; airline deferred maintenance plans and the availability and pricing of new and used space parts and material; the pace of aircraft retirements and the changes in the age of the active aircraft fleet; continued demand for dedicated cargo aircraft and the pace of passenger-to-freighter conversions; production schedules and successful rate breaks for key commercial transport programs; the management of COVID-related risks to end-market demand and the potential for further supply chain and logistics disruptions; the ability to hire and train the necessary human capital to achieve growth objectives; potential supply chain disruptions and extended lead-times that could impact company, customer, or supplier delivery schedules; raw material costs and availability; the M&A pipeline and the company's ability to successfully execute and integrate subsequent acquisitions; the company's ability to access capital and financial liquidity to support its


growth objectives; cost management and free cash flow generation; interest rates and the ability to access capital and to service current debt obligations; the top-line level of defense spending and funding for specific company programs; the timing of the FY22 defense budget completion and impact of the Continuing Resolution; the ongoing DoD OIG audit and potential fines or other penalties; and the timing and opportunity for foreign military sales.

### Exhibit 51 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 52 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)



## UnitedHealth Group Inc. (NYSE: UNH)

RBC Capital Markets, LLC

Ben Hendrix (Analyst) (615) 372-1323, [ben.hendrix@rbccm.com](mailto:ben.hendrix@rbccm.com)
**Rating: Outperform**
**Closing Price: USD 517.40**
**Price Target: USD 588.00**
**Implied All-in Return (%): 14.6**

### Investment summary

With the impressive scale of its enterprise and breadth of integrated service offerings, UnitedHealth Group touches virtually every segment of the US healthcare continuum. And yet despite its scale, we believe the company offers investors a strong growth profile and excellent visibility, with EPS increasing at a targeted 13–16% clip annually and significant room to run over the long term.

UNH has evolved in recent years such that Optum continues to grow in terms of importance and impact on the enterprise, now expected to generate just over half of earnings and representing a significant growth engine for the company as it executes on its integrated product offering—even as it just scratches the surface of its addressable market both domestically and globally.

In the legacy UnitedHealthcare medical benefits segment, the company is already the industry leader in nearly every business segment, but it continues to exceed market growth rates in Medicare and Medicaid, leveraging its significant scalability while remaining disciplined in pricing.

In addition, UNH continues to generate very strong cash flow, which along with the solid balance sheet provides significant flexibility to invest in growth opportunities and shareholder-friendly returns.


### Valuation

Our price target of \$588 is based on a P/E multiple of 26x the high end of management's FY22E adjusted EPS range, plus \$0.90 to normalize for expected residual COVID headwinds. We continue to believe UNH deserves a premium valuation relative to the group given its diversified platform with the higher-growth Optum segment and the company's proven ability to execute operationally, leading to earnings estimate beat and raises. We have raised our target multiple by one turn to reflect faster than expected onboarding of value-based membership through the first quarter. Our target multiple continues to represent expansion beyond UNH's historical peak valuations to account for the significant growth opportunity we see in the Optum platform through enhanced integration with UNH and advancement of value-based care models. Our price target supports our Outperform rating.

### Risks to rating and price target


Risks to rating and price target include: 1) execution risk in predicting and managing medical cost trends; 2) execution risk in network contracting; 3) regulatory risk; 4) reimbursement risk in the government business; and 5) protracted economic downturn as a result of the COVID-19 outbreak could impact the earnings growth trajectory.

### Exhibit 53 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 54 - Forward consensus P/E history



Source: Factset

**Most recent company note: [link](#)**

## Veeva Systems Inc. (NYSE: VEEV)

**RBC Capital Markets, LLC**  
**Rishi Jaluria (Analyst) (415) 633-8798, [rishi.jaluria@rbccm.com](mailto:rishi.jaluria@rbccm.com)**

## Investment summary

We like shares of Veeva for four primary reasons:

**Veeva's domain expertise and deep customer relationships** have created a market leadership position and a sustainable economic moat, limiting the threat of competition. As a result, Veeva has one of the highest average revenues per customer in software (~\$1.6M last year).

**We see multiple growth drivers for Veeva** to maintain 20%+ subscription growth, including CDMS, Data Cloud, and Vault OLS (outside of life sciences). We believe Veeva has a large TAM that will continue to grow with new products and that Vault, Veeva's content management platform, is a continued engine for innovation.

**Veeva's financial model is best-in-class**, with a leading blend of growth and profitability. Veeva continues to show 20%+ organic subscription growth, while also seeing FCF margins approach 40% (which places Veeva in rare territory among SaaS companies), making Veeva a consistent "Rule of 40" company. This is the result of Veeva's product-led growth, fiscal discipline, and its unique GTM motion of the "Veeva Way", which involves slowly driving adoption through reference selling.

**The life sciences market is attractive**, as it is a defensive industry that is also rather profitable (pharmaceutical companies have software-like gross margins of 70%+) and technology-forward (with the pandemic accelerating digital transformation initiatives). One key feature of life sciences is the industry is more collaborative than others, which makes reference selling a key part of the GTM model. In addition, Veeva's blue

chip customer base spans almost all the top pharmaceutical companies, including household names like Pfizer, Moderna, Johnson & Johnson, AstraZeneca, and Regeneron.

## Valuation

Our \$250 price target is based on 39x EV/CY23E FCF, a premium to the peer group which we believe is warranted considering Veeva's leading blend of growth and margins, runway for future growth, and competitive positioning. Our price target supports our Outperform rating.

### Risks to rating and price target

Risks to rating and price target: 1) customer concentration, with the top 10 customers representing 36% of revenue; 2) international risk, with non-US revenue representing ~40% of total revenue; 3) CRM remains a significant part of the business at ~45% of total revenue (according to our estimates); 4) competition, including from vertical and horizontal software vendors; and 5) Veeva has a dual class share structure, with Class B shares holding ~52% voting power which limits the ability of investors to effect change at Veeva.


**Rating: Outperform**

**Price Target: USD 250.00**

**Closing Price: USD 204.11**


**Implied All-in Return (%): 22.5**

### Exhibit 55 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

Exhibit 56 - Forward consensus EV/EBITDA history



Source: Factset

Most recent company note: [link](#)

## WESCO International, Inc. (NYSE: WCC)

RBC Capital Markets, LLC

Deane Dray, CFA (Analyst) (212) 428-6465, [deane.dray@rbccm.com](mailto:deane.dray@rbccm.com)

Rating: Outperform

Closing Price: USD 105.83

Price Target: USD 195.00

Implied All-in Return (%): 84.3

### Investment summary

WESCO is the leading North America based electrical distributor in the +\$100 billion highly fragmented North American electrical products distribution market with an estimated 7% market share, and 13% post-Anixter deal. We admire the scrappy, no-frills attitude that runs throughout the organization, as well as the strong historical free cash flow and debt pay-down history. After it emerged victorious from the Anixter bidding war, we estimate compelling upside based on pro-forma EPS and historically low multiples. We also like the fundamental scale benefits that come with the deal, including greater bargaining power with customers and suppliers that should help the company battle the ongoing tough price/cost backdrop.

### Valuation

Our \$195 price target assumes WCC trades to an undemanding 35% discount to our 18.0x SMID-cap 2023 target group P/E multiple, or 11.7x. This is below the midpoint of WCC's historical (40%)-(10%) relative P/E range to discount the elevated leverage and integration risk following the Anixter deal balanced by its attractive leverage to the powerful secular themes of Electrification, Grid-Hardening, Sustainability/Decarbonization. Our price target supports our Outperform rating.

### Risks to rating and price target

#### Integration risk with Anixter.

**Economic conditions.** WESCO operates in cyclical industrial end markets and a slowdown in global activity could adversely impact sales and operating margins. Macro trends including inflation/deflation, commodity

costs, credit availability, currency fluctuations, and supply chain could all materially impact results.

**Competition and pricing.** WESCO operates in the highly fragmented and competitive electrical products distribution market. With limited access to credit, smaller competitors may potentially cut prices and pressure WESCO's disciplined business model. There is also a growing risk from online distributors such as Amazon Business.


**Acquisitions.** WESCO has been active on the M&A front in this consolidating market and is exposed to overpaying for targets and integration headwinds. We remain confident in management's discipline on this front but acknowledge that large deals such as EECOL require considerable management attention and carry inherent integration risk.

**Financial risks.** Tightening credit standards and any disruption to credit markets could cause our estimates to be too optimistic.

**Nonresidential end market.** A slower-than-expected recovery in the nonresidential construction end-market could cause our estimates to be too optimistic.


**COVID-19 impacts.** WESCO's operations have exposure to the COVID-19 pandemic.

### Exhibit 57 - Share performance and RBC valuation



Source: Bloomberg and RBC Capital Markets estimates for Target

### Exhibit 58 - Forward consensus P/E history



Source: Factset

Most recent company note: [link](#)

## Required disclosures

### Non-U.S. analyst disclosure

One or more research analysts involved in the preparation of this report (i) may not be registered/qualified as research analysts with the NYSE and/or FINRA and (ii) may not be associated persons of the RBC Capital Markets, LLC and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

### Conflicts disclosures

This product constitutes a compendium report (covers six or more subject companies). As such, RBC Capital Markets chooses to provide specific disclosures for the subject companies by reference. To access conflict of interest and other disclosures for the subject companies, clients should refer to <https://www.rbccm.com/GLDisclosure/PublicWeb/DisclosureLookup.aspx?entityId=1>. These disclosures are also available by sending a written request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7 or an email to [rbcinsight@rbccm.com](mailto:rbcinsight@rbccm.com).

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors, including total revenues of the member companies of RBC Capital Markets and its affiliates, a portion of which are or have been generated by investment banking activities of the member companies of RBC Capital Markets and its affiliates.

With regard to the MAR investment recommendation requirements in relation to relevant securities, a member company of Royal Bank of Canada, together with its affiliates, may have a net long or short financial interest in excess of 0.5% of the total issued share capital of the entities mentioned in the investment recommendation. Information relating to this is available upon request from your RBC investment advisor or institutional salesperson.

### Explanation of RBC Capital Markets Equity rating system

An analyst's "sector" is the universe of companies for which the analyst provides research coverage. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12 months relative to the analyst's sector average.

#### Ratings

**Outperform (O):** Expected to materially outperform sector average over 12 months.

**Sector Perform (SP):** Returns expected to be in line with sector average over 12 months.

**Underperform (U):** Returns expected to be materially below sector average over 12 months.

**Restricted (R):** RBC policy precludes certain types of communications, including an investment recommendation, when RBC is acting as an advisor in certain merger or other strategic transactions and in certain other circumstances.

**Not Rated (NR):** The rating, price targets and estimates have been removed due to applicable legal, regulatory or policy constraints which may include when RBC Capital Markets is acting in an advisory capacity involving the company.

As of March 31, 2020, RBC Capital Markets discontinued its Top Pick rating. Top Pick rated securities represented an analyst's best idea in the sector; expected to provide significant absolute returns over 12 months with a favorable risk-reward ratio. Top Pick rated securities have been reassigned to our Outperform rated securities category, which are securities expected to materially outperform sector average over 12 months.

**Risk Rating:** The **Speculative** risk rating reflects a security's lower level of financial or operating predictability, illiquid share trading volumes, high balance sheet leverage, or limited operating history that result in a higher expectation of financial and/or stock price volatility.

## Distribution of ratings

For the purpose of ratings distributions, regulatory rules require member firms to assign ratings to one of three rating categories - Buy, Hold/Neutral, or Sell - regardless of a firm's own rating categories. Although RBC Capital Markets' ratings of Outperform (O), Sector Perform (SP), and Underperform (U) most closely correspond to Buy, Hold/Neutral and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis.

Distribution of ratings				
RBC Capital Markets, Equity Research				
As of 30-Jun-2022				
Rating	Count	Percent	Investment Banking	
			Serv./Past 12 Mos.	
			Count	Percent
BUY [Outperform]	851	58.41	290	34.08
HOLD [Sector Perform]	560	38.44	169	30.18
SELL [Underperform]	46	3.16	6	13.04

## Conflicts policy

RBC Capital Markets Policy for Managing Conflicts of Interest in Relation to Investment Research is available from us on request. To access our current policy, clients should refer to <https://www.rbccm.com/global/file-414164.pdf> or send a request to RBC Capital Markets Research Publishing, P.O. Box 50, 200 Bay Street, Royal Bank Plaza, 29th Floor, South Tower, Toronto, Ontario M5J 2W7. We reserve the right to amend or supplement this policy at any time.

## Dissemination of research

RBC Capital Markets endeavors to make all reasonable efforts to provide research content simultaneously to all eligible clients, having regard to local time zones in overseas jurisdictions. RBC Capital Markets provides eligible clients with access to Research Reports on the Firm's proprietary INSIGHT website, via email and via third-party vendors. Please contact your investment advisor or institutional salesperson for more information regarding RBC Capital Markets' research.

For a list of all recommendations on the company that were disseminated during the prior 12-month period, please click on the following link:

<https://rbnew.bluematrix.com/sellside/MAR.action>

The 12 month history of SPARCs can be viewed at <https://www.rbcinsightresearch.com/>.



## Analyst certification

All of the views expressed in this report accurately reflect the personal views of the responsible analyst(s) about any and all of the subject securities or issuers. No part of the compensation of the responsible analyst(s) named herein is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the responsible analyst(s) in this report.

## Third-party disclaimers

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P") and is licensed for use by RBC. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

RBC Capital Markets disclaims all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any statements made to the media or via social media that are in turn quoted in this report, or otherwise reproduced graphically for informational purposes.



## Disclaimer

RBC Capital Markets is the business name used by certain branches and subsidiaries of the Royal Bank of Canada, including RBC Dominion Securities Inc., RBC Capital Markets, LLC, RBC Europe Limited, RBC Capital Markets (Europe) GmbH, Royal Bank of Canada, Hong Kong Branch, Royal Bank of Canada, Singapore Branch and Royal Bank of Canada, Sydney Branch. The information contained in this report has been compiled by RBC Capital Markets from sources believed to be reliable, but no representation or warranty, express or implied, is made by Royal Bank of Canada, RBC Capital Markets, its affiliates or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute RBC Capital Markets' judgement as of the date of this report, are subject to change without notice and are provided in good faith but without legal responsibility. Nothing in this report constitutes legal, accounting or tax advice or individually tailored investment advice. This material is prepared for general circulation to clients and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The investments or services contained in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about the suitability of such investments or services. This report is not an offer to sell or a solicitation of an offer to buy any securities. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. RBC Capital Markets research analyst compensation is based in part on the overall profitability of RBC Capital Markets, which includes profits attributable to investment banking revenues. Every province in Canada, state in the U.S., and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, the securities discussed in this report may not be eligible for sale in some jurisdictions. RBC Capital Markets may be restricted from publishing research reports, from time to time, due to regulatory restrictions and/or internal compliance policies. If this is the case, the latest published research reports available to clients may not reflect recent material changes in the applicable industry and/or applicable subject companies. RBC Capital Markets research reports are current only as of the date set forth on the research reports. This report is not, and under no circumstances should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. To the full extent permitted by law neither RBC Capital Markets nor any of its affiliates, nor any other person, accepts any liability whatsoever for any direct, indirect or consequential loss arising from, or in connection with, any use of this report or the information contained herein. No matter contained in this document may be reproduced or copied by any means without the prior written consent of RBC Capital Markets in each instance.

### Additional information is available on request.

**To U.S. Residents:** This publication has been approved by RBC Capital Markets, LLC (member FINRA, NYSE, SIPC), which is a U.S. registered broker-dealer and which accepts responsibility for this report and its dissemination in the United States. Any U.S. recipient of this report that is not a registered broker-dealer or a bank acting in a broker or dealer capacity and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, should contact and place orders with RBC Capital Markets, LLC.

**To Canadian Residents:** This publication has been approved by RBC Dominion Securities Inc. (member IIROC). Any Canadian recipient of this report that is not a Designated Institution in Ontario, an Accredited Investor in British Columbia or Alberta or a Sophisticated Purchaser in Quebec (or similar permitted purchaser in any other province) and that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report should contact and place orders with RBC Dominion Securities Inc., which, without in any way limiting the foregoing, accepts responsibility for this report and its dissemination in Canada.

**To U.K. Residents:** This publication has been approved by RBC Europe Limited ('RBCEL') which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority ('FCA') and the Prudential Regulation Authority, in connection with its distribution in the United Kingdom. This material is not for general distribution in the United Kingdom to retail clients, as defined under the rules of the FCA. RBCEL accepts responsibility for this report and its dissemination in the United Kingdom.

**To EEA Residents:** This material is distributed in the EU by either RBCEL on an authorised cross-border basis, or by RBC Capital Markets (Europe) GmbH (RBC EG) which is authorised and regulated in Germany by the Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) (BaFin).

**To Persons Receiving This Advice in Australia:** This material has been distributed in Australia by Royal Bank of Canada, Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product and consider that document before making any decision about whether to acquire the product. This research report is not for retail investors as defined in section 761G of the Corporations Act.

**To Hong Kong Residents:** This publication is distributed in Hong Kong by Royal Bank of Canada, Hong Kong Branch, which is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission (SFC) in Hong Kong, RBC Investment Services (Asia) Limited and RBC Global Asset Management (Asia) Limited, both entities are regulated by the SFC. This material is not for general distribution in Hong Kong to persons who are not professional investors (as defined in the Securities and Futures Ordinance of Hong Kong (Cap. 571) and any rules made thereunder).

**To Singapore Residents:** This publication is distributed in Singapore by the Royal Bank of Canada, Singapore Branch, a registered entity licensed by the Monetary Authority of Singapore. This material has been prepared for general circulation and does not take into account the objectives, financial situation, or needs of any recipient. You are advised to seek independent advice from a financial adviser before purchasing any product. If you do not obtain independent advice, you should consider whether the product is suitable for you. Past performance is not indicative of future performance. If you have any questions related to this publication, please contact the Royal Bank of Canada, Singapore Branch. Royal Bank of Canada, Singapore Branch accepts responsibility for this report and its dissemination in Singapore.

**To Japanese Residents:** Unless otherwise exempted by Japanese law, this publication is distributed in Japan by or through RBC Capital Markets (Japan) Ltd. which is a Financial Instruments Firm registered with the Kanto Local Financial Bureau (Registered number 203) and a member of the Japan Securities Dealers Association ("JSDA") and the Financial Futures Association of Japan ("FFAJ").

® Registered trademark of Royal Bank of Canada. RBC Capital Markets is a trademark of Royal Bank of Canada. Used under license.

Copyright © RBC Capital Markets, LLC 2022 - Member SIPC

Copyright © RBC Dominion Securities Inc. 2022 - Member Canadian Investor Protection Fund

Copyright © RBC Europe Limited 2022

Copyright © Royal Bank of Canada 2022

All rights reserved